Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Semaglutide — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Semaglutide updates

See full history →

Semaglutide + Insulin Icodec for Type 2 Diabetes Shows HbA1c Reduction· Jun 3, 2026
Ozempic Label Adds Boxed Warning for Thyroid C-Cell Tumors· May 19, 2026
Semaglutide Achieves -12.2% Weight Loss in Overweight/Obesity Study· May 18, 2026
Semaglutide + Lower Insulin Glargine Reduces HbA1c, Weight in T2D· May 11, 2026
Semaglutide Oral Tablet Shows Significant Weight Loss in Obesity Trial· May 7, 2026
Semaglutide Biosimilar Trial vs. Wegovy in Obesity Completes Phase 3· Apr 30, 2026
Semaglutide 7.2 mg Shows Superior Weight Loss in Obesity, Type 2 Diabetes· Apr 27, 2026
Semaglutide for Obesity: Phase 3 Trial Shows Significant Weight Loss vs. Placebo· Apr 23, 2026

What Is Semaglutide?

Semaglutide is an FDA-approved medication for Type 2 Diabetes Mellitus and for weight management in adults with obesity. It is a glucagon-like peptide-1 (GLP-1) receptor agonist. This means it works by mimicking a natural hormone in the body that helps regulate blood sugar and appetite. Primarily, semaglutide helps to control blood glucose levels by counteracting insulin resistance and can also lead to weight loss. Beyond its approved uses, semaglutide is being investigated in numerous clinical trials for a variety of other conditions. These include metabolic dysfunction-associated steatohepatitis (MASH), nonalcoholic fatty liver disease (NAFLD), alcohol use disorder, methamphetamine use disorder, and cocaine use disorder. Researchers are also exploring its potential in conditions such as Parkinson's disease, atrial fibrillation, and certain types of lung disease. In total, there are 537 trials involving semaglutide, with the first trial starting in 2008 and the latest projected to conclude in 2026.

Uses and Conditions Under Study

Semaglutide is widely studied for its effects on metabolic health. The most common conditions under investigation are related to diabetes and weight management.

Diabetes and Metabolic Conditions: Semaglutide is approved for Type 2 Diabetes Mellitus and is being studied in 157 trials for Diabetes Mellitus, Type 2, 68 for Diabetes, and 45 for Type 2 Diabetes. It helps control blood glucose and may counteract insulin resistance. Some trials are also exploring its use in Type 1 Diabetes, often in combination with insulin, and for conditions like polycystic ovary syndrome (PCOS) which can involve metabolic disturbances.
Obesity and Weight Management: With 129 trials for Obesity, 32 for Overweight, and 10 for Weight Loss, semaglutide is a key focus for weight management. It is also being studied for obesity associated with other conditions, such as antipsychotic-induced weight gain, obstructive sleep apnea (OSA), and in patients with bipolar disorder who also have obesity.
Liver Conditions: Semaglutide is being investigated for its potential to treat metabolic dysfunction-associated steatohepatitis (MASH) and nonalcoholic fatty liver disease (NAFLD), conditions where excess fat builds up in the liver, leading to inflammation and damage.
Substance Use Disorders: Researchers are exploring semaglutide's effects on cravings and substance use in trials for alcohol use disorder (NCT05221008, NCT05794829), methamphetamine use disorder (NCT05860718), cocaine use disorder (NCT06067757), and tobacco use cessation.
Cardiovascular and Other Conditions: Studies are also underway for conditions such as atrial fibrillation (AF) in patients with obesity (NCT05716170), osteosarcopenia in older females with type 2 diabetes (NCT05986874), and chronic spinal cord injury with cardiometabolic diseases. Other investigational uses include autonomous cortisol secretion (MACS), advanced lung disease, asthma with excess body weight, and Parkinson's disease (NCT05741018).

A total of 2,376,243 participants have been enrolled across all semaglutide trials, including studies involving healthy volunteers to assess drug properties.

Dosing

Semaglutide is available in several forms, including subcutaneous injections and oral tablets. The specific dosage and administration method depend on the condition being treated and the formulation. For subcutaneous injections, semaglutide is typically administered once weekly. Doses studied range from 0.25 mg to 2.4 mg per week. Initial dosing often starts at a lower strength, such as 0.25 mg for the first 4 weeks, with gradual titration up to a maximum tolerated dose or 2.4 mg weekly starting at week 5. Different concentrations, such as 0.68 mg/mL and 1.34 mg/mL, have been investigated to assess how the drug moves through the body when delivered via various injection tools. Oral semaglutide is typically taken once daily. Common strengths studied for oral tablets include 3 mg, 7 mg, and 14 mg. Higher investigational doses of 25 mg and 50 mg have also been explored. The effectiveness of oral semaglutide can be influenced by factors such as the volume of water taken with the tablet and the time delay between taking the tablet and eating a meal. Semaglutide is also being studied in combination with other investigational medicines, such as cagrilintide, NNC0480-0389, and CS060380, to explore enhanced therapeutic effects. While primarily studied in adults, pediatric dosing is under investigation for children and teenagers for weight loss, with studies differentiating between pubertal and post-pubertal adolescents. Other investigational forms include nasal sprays and implants.

Side Effects

The most common side effect reported by patients taking Semaglutide in clinical trials was nausea. Across 52 trials involving over 31,000 patients, 23.1% of those on Semaglutide experienced nausea, compared to 6.4% on placebo.

Other common side effects reported more frequently with Semaglutide than with placebo included:

Diarrhea: 16.8% of patients on Semaglutide experienced diarrhea, compared to 7.7% on placebo.
Constipation: 12.7% of patients on Semaglutide experienced constipation, compared to 4.5% on placebo.
Vomiting: 12.3% of patients on Semaglutide experienced vomiting, compared to 3.0% on placebo.
Headache: 9.8% of patients on Semaglutide experienced headache, compared to 7.7% on placebo.
Decreased appetite: 8.6% of patients on Semaglutide experienced decreased appetite, compared to 2.3% on placebo.
Dyspepsia (indigestion): 7.1% of patients on Semaglutide experienced dyspepsia, compared to 2.1% on placebo.
Fatigue: 6.9% of patients on Semaglutide experienced fatigue, compared to 4.0% on placebo.
Abdominal pain: 6.7% of patients on Semaglutide experienced abdominal pain, compared to 3.6% on placebo.

Clinical Trial Results

Condition: Type 2 Diabetes

Clinical trials have evaluated Semaglutide's effectiveness in managing Type 2 Diabetes, often comparing it to placebo or other diabetes medications.

Trial NCT00696657: Semaglutide vs. Placebo and Liraglutide

This trial compared various doses of Semaglutide to placebo and another medication, Liraglutide, in patients with Type 2 Diabetes. Key findings include:

HbA1c Reduction: Semaglutide significantly reduced HbA1c (a measure of average blood sugar). Patients taking the highest dose of Semaglutide 1.6 mg (With Titration) saw an average HbA1c reduction of 1.5 percentage points, compared to a 0.5 percentage point reduction with placebo. Liraglutide 1.8 mg also reduced HbA1c by 1.3 percentage points.
Blood Pressure: Semaglutide 0.8 mg (With Titration) reduced systolic blood pressure by 7.7 mmHg and diastolic blood pressure by 2.3 mmHg. Semaglutide 1.6 mg (With Titration) reduced systolic blood pressure by 5.9 mmHg and diastolic blood pressure by 3.0 mmHg. Placebo reduced systolic blood pressure by 3.2 mmHg and diastolic blood pressure by 2.3 mmHg.
Pulse Rate: Semaglutide 1.6 mg (With Titration) increased pulse rate by an average of 3.9 beats per minute, while placebo increased it by 0.5 beats per minute.
Adverse Events: A higher percentage of patients on Semaglutide experienced adverse events, with 93.6% of those on Semaglutide 1.6 mg (With Titration) reporting an event, compared to 43.5% on placebo.

Trial NCT01720446: Cardiovascular Outcomes with Semaglutide

This long-term trial assessed Semaglutide's impact on cardiovascular health in patients with Type 2 Diabetes.

Cardiovascular Events: Semaglutide reduced the risk of major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. 6.6% of patients on Semaglutide experienced a MACE, compared to 8.9% on placebo.
Expanded Cardiovascular Outcomes: For an expanded composite cardiovascular outcome, 12.1% of patients on Semaglutide experienced an event, compared to 16.0% on placebo.
Body Weight: Patients treated with Semaglutide 1.0 mg experienced an average body weight reduction of 4.88 kg, compared to a 0.62 kg reduction with placebo.
HbA1c Reduction: Semaglutide 1.0 mg reduced HbA1c by 1.41 percentage points, while placebo reduced it by 0.36 percentage points.
Urinary Albumin to Creatinine Ratio: Semaglutide 1.0 mg reduced this ratio to 0.91 mg/g, suggesting a positive effect on kidney health, compared to 1.29 mg/g with placebo.

Trial NCT01885208: Semaglutide vs. Exenatide ER

This study compared Semaglutide to Exenatide ER in patients also taking oral antidiabetic drugs.

HbA1c Reduction: Patients on Semaglutide 1.0 mg achieved an average HbA1c reduction of 1.54 percentage points, which was greater than the 0.92 percentage point reduction seen with Exenatide ER 2.0 mg.
HbA1c Target Achievement: 53.0% of patients on Semaglutide 1.0 mg reached an HbA1c target of 6.5% or less, compared to 22.0% of patients on Exenatide ER 2.0 mg.
Body Weight: Semaglutide 1.0 mg led to an average body weight reduction of 5.63 kg, significantly more than the 1.85 kg reduction with Exenatide ER 2.0 mg.

Trial NCT01923181: Oral Semaglutide Dose Range

This trial explored different doses of oral Semaglutide.

HbA1c Reduction: Oral Semaglutide 40 mg reduced HbA1c by an average of 2.04 percentage points, compared to a 0.40 percentage point reduction with placebo. Subcutaneous Semaglutide 1 mg achieved a 1.85 percentage point reduction.
Body Weight: Oral Semaglutide 40 mg led to an average body weight reduction of 6.91 kg, compared to 1.16 kg with placebo. Subcutaneous Semaglutide 1 mg resulted in a 6.71 kg reduction.

Trial NCT01930188: Semaglutide vs. Sitagliptin

This study compared Semaglutide to Sitagliptin as an add-on therapy.

HbA1c Reduction: Semaglutide 1.0 mg reduced HbA1c by 1.61 percentage points, while Sitagliptin reduced it by 0.55 percentage points.
HbA1c Target Achievement: 66.0% of patients on Semaglutide 1.0 mg achieved an HbA1c of 6.5% or less, compared to 20.4% of patients on Sitagliptin.
Body Weight: Semaglutide 1.0 mg resulted in an average body weight reduction of 6.13 kg, compared to a 1.93 kg reduction with Sitagliptin.

Currently Recruiting Trials

Clinical trials are currently exploring the potential of semaglutide for a wide range of health conditions, from diabetes and obesity to more novel applications. These studies aim to understand how semaglutide works, its effectiveness, and its safety. Participating in a clinical trial offers an opportunity to contribute to medical research and potentially access new treatments. One study, NCT07415954, is a Phase 2 trial sponsored by Novo Nordisk A/S, enrolling 270 people with Type 2 Diabetes. It compares different doses of an investigational medicine, NNC0662-0419, against placebo and semaglutide to assess its effect on blood sugar. Another Phase 2 trial, NCT07527195 is a Phase 1 study by Novo Nordisk A/S, enrolling 100 participants to understand how semaglutide, cagrilintide, and their combination (CagriSema) affect muscle health during weight loss. Cascade Pharmaceuticals, Inc. is sponsoring NCT07466017, a Phase 2 study with 120 participants, to evaluate a new medicine, CS060380, when combined with semaglutide for adults with metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Exploring new ways to administer semaglutide, Shanghai World Leader Pharmaceutical Co., Ltd. is conducting NCT07465965, a Phase 1 trial with 60 overweight or obese adults, to examine the safety, tolerability, and pharmacokinetics of a semaglutide nasal spray compared to placebo and injected semaglutide. In a different area of research, Brigham and Women's Hospital is sponsoring NCT06639464, a Phase 2 pilot trial with 46 participants, to determine if semaglutide can help individuals with opioid use disorder who are starting buprenorphine treatment. Additionally, a Phase 4 trial, NCT07242534, at Fundacion Dexeus, is enrolling 62 overweight and obese women undergoing in vitro fertilization to see if 12 weeks of semaglutide pre-treatment improves embryo quality.

Where to Participate

Clinical trials for semaglutide are being conducted across a broad geographical area, offering many opportunities for participation. Currently, there are 125 study sites located in 104 cities and 37 states. Some of the cities with the most active recruiting sites include:

San Antonio, Texas (8 sites)
Aurora, Colorado (6 sites)
Houston, Texas (5 sites)
Miami, Florida (4 sites)
Baltimore, Maryland (4 sites)
Baton Rouge, Louisiana (4 sites)
Jacksonville, Florida (3 sites)
Boston, Massachusetts (3 sites)
Nashville, Tennessee (3 sites)
Seattle, Washington (3 sites)

These studies welcome a wide range of participants, with eligibility generally open to individuals aged 8 to 110 years, regardless of gender. Many trials also seek healthy volunteers and children, depending on the specific research focus.

Development Timeline

The journey of semaglutide began with its first clinical trial on June 13, 2008, marking the start of extensive research into its therapeutic potential. Since then, development has been largely driven by Novo Nordisk A/S, which has sponsored 234 of the 537 total trials conducted to date. This robust research effort has enrolled over 2.3 million participants, exploring semaglutide's effects across various health conditions. Initially, studies focused on conditions like IBS-C and hyperphosphatemia, but the pipeline quickly expanded to address major metabolic disorders. Early and significant efforts concentrated on Type 2 Diabetes, overweight, and obesity, progressing through Phase 1, Phase 2, and Phase 3 trials. As understanding of semaglutide's mechanisms grew, its potential applications broadened considerably. The development timeline shows a consistent progression through all phases of clinical research, with 138 Phase 3 trials and 104 Phase 1 trials completed or ongoing. This expansion has led to investigations into a diverse array of conditions, including Type 1 Diabetes, non-alcoholic fatty liver disease (NAFLD), cardiovascular diseases, heart failure, HIV, diabetic kidney disease, metabolic syndrome, and even neurological conditions like Alzheimer's disease. The latest trial is projected to conclude in 2026, indicating ongoing commitment to uncovering further benefits of this versatile medication.

Semaglutide Development Timeline

Clinical trial activity from 2007 to 2027.

2027

NCT07430332PHASE2not yet recruiting

GLP-1 RA for Stage 1 Type 1 Diabetes

15 enrolled

NCT06977438PHASE4not yet recruiting

Promoting Healthy Children and Youth

1,020 enrolled

2026

NCT07389941PHASE4not yet recruiting

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

240 enrolled

NCT07282613PHASE3not yet recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

80 enrolled

NCT07411378PHASE2not yet recruiting

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

164 enrolled

NCT07218354PHASE3not yet recruiting

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

622 enrolled

NCT07511543PHASE2not yet recruiting

Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

100 enrolled

NCT07282769PHASE2not yet recruiting

Semaglutide (Wegovy) Treatment for Trichotillomania

10 enrolled

NCT07570810NAnot yet recruiting

Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

30 enrolled

NCT06934655PHASE3not yet recruiting

Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

150 enrolled

NCT07509112PHASE2not yet recruiting

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

40 enrolled

NCT07564414PHASE3recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

2,500 enrolled

NCT07400107PHASE3not yet recruiting

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

1,000 enrolled

NCT06546384NAnot yet recruiting

GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

64 enrolled

NCT07021937PHASE3not yet recruiting

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

120 enrolled

NCT07485062PHASE4not yet recruiting

Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes

164 enrolled

NCT07179120PHASE2not yet recruiting

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

180 enrolled

NCT07523633PHASE2recruiting

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

100 enrolled

NCT07428746PHASE3not yet recruiting

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

20 enrolled

NCT07430059PHASE1not yet recruiting

Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

20 enrolled

NCT07547878PHASE4not yet recruiting

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

64 enrolled

NCT07415954PHASE2recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

270 enrolled

NCT07221214PHASE2recruiting

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

200 enrolled

NCT07527195PHASE1recruiting

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

100 enrolled

NCT07554417PHASE4not yet recruiting

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

20 enrolled

NCT07466017PHASE2recruiting

A Study of CS060380 Tablets in Patients With MASH and Obesity

120 enrolled

NCT07483801PHASE4not yet recruiting

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

112 enrolled

NCT07424430not yet recruiting

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

400 enrolled

NCT07446998PHASE2recruiting

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

200 enrolled

NCT07317115NArecruiting

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

20 enrolled

NCT07505303PHASE2not yet recruiting

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

160 enrolled

NCT07223983PHASE1recruiting

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

10 enrolled

NCT07361874NArecruiting

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

75 enrolled

NCT07465965PHASE1recruiting

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

60 enrolled

NCT06975111PHASE2/PHASE3recruiting

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

200 enrolled

NCT06222437PHASE1withdrawn

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

0 enrolled

NCT07204249PHASE2recruiting

Glutide for Ending Methamphetamine

162 enrolled

NCT06836284NArecruiting

The Evira Study: Additional Support During Obesity Treatment

40 enrolled

NCT07059377PHASE3recruiting

Semaglutide for Smoking Cessation in Patients With Diabetes

100 enrolled

NCT07325500PHASE2recruiting

Incretin Microdosing for Cardiometabolic Health in People With HIV

30 enrolled

NCT07195994NArecruiting

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

90 enrolled

NCT05689372enrolling by invitation

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

600 enrolled

NCT07294950PHASE3recruiting

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

98 enrolled

NCT07323134not yet recruiting

The Effect of Semaglutide on the Intestinal Flora in Obesity

40 enrolled

NCT07391267NAnot yet recruiting

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

90 enrolled

NCT07187856PHASE2not yet recruiting

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

80 enrolled

NCT07417618active not recruiting

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

60,000 enrolled

NCT07390110active not recruiting

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

25,664 enrolled

NCT07202247PHASE2recruiting

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

60 enrolled

NCT07213466PHASE4recruiting

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

100 enrolled

NCT07242534PHASE4recruiting

Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

62 enrolled

NCT07227948PHASE2recruiting

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

75 enrolled

NCT07401992PHASE4recruiting

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

62 enrolled

NCT07040592PHASE2recruiting

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

30 enrolled

NCT07253285PHASE3recruiting

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

460 enrolled

NCT07172867PHASE2withdrawn

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

0 enrolled

NCT06913023PHASE2/PHASE3not yet recruiting

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

74 enrolled

NCT07135245PHASE2not yet recruiting

Improved Treatment and Monitoring of Alzheimer's Disease

180 enrolled

2025

NCT05714683not yet recruiting

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

600 enrolled

NCT07295223PHASE3recruiting

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

44 enrolled

NCT07284979PHASE3recruiting

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

1,200 enrolled

NCT07297589PHASE3recruiting

Epicardial Cardiac Fat-CT (EPIC-CT)

136 enrolled

NCT07319975NAnot yet recruiting

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

48 enrolled

NCT07285902PHASE3active not recruiting

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

572 enrolled

NCT07275697PHASE4not yet recruiting

Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

200 enrolled

NCT07271251PHASE3active not recruiting

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

264 enrolled

NCT07251556PHASE4not yet recruiting

GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

40 enrolled

NCT07302802recruiting

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

70 enrolled

NCT06954090PHASE4enrolling by invitation

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

50 enrolled

NCT07280221enrolling by invitation

WEgovy Real World Assessment of Weight Loss in Korea

500 enrolled

NCT07225816PHASE1recruiting

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

75 enrolled

NCT06909006PHASE3not yet recruiting

Semaglutide Treatment in Type 1 Diabetes

122 enrolled

NCT07073053PHASE4not yet recruiting

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

60 enrolled

NCT06801015PHASE4active not recruiting

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

30 enrolled

NCT07184086PHASE1recruiting

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

80 enrolled

NCT07200622PHASE2not yet recruiting

Oral Semaglutide in Patients With Alzheimer's Disease

60 enrolled

NCT07150975PHASE3recruiting

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

420 enrolled

NCT07165158PHASE4not yet recruiting

The Effect of Semaglutide on Bone Health

150 enrolled

NCT07136714PHASE4recruiting

Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

116 enrolled

NCT07314684PHASE4recruiting

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

80 enrolled

NCT07139548PHASE3not yet recruiting

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

600 enrolled

NCT07112872PHASE2active not recruiting

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

240 enrolled

NCT07091500NArecruiting

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

40 enrolled

NCT07081178terminated

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

100 enrolled

NCT06691243PHASE2recruiting

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

40 enrolled

NCT07065383NArecruiting

Rebalancing the Fat Content of the Heart and Muscles

60 enrolled

NCT07513168PHASE4recruiting

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

60 enrolled

NCT07017270PHASE4not yet recruiting

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

100 enrolled

NCT07073417PHASE2active not recruiting

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

163 enrolled

NCT07254572PHASE4recruiting

Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

300 enrolled

NCT07064486PHASE3recruiting

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

477 enrolled

NCT06908694PHASE4recruiting

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

20 enrolled

NCT07030621PHASE3not yet recruiting

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

436 enrolled

NCT07087795PHASE1active not recruiting

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

96 enrolled

NCT07101939PHASE2recruiting

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

120 enrolled

NCT07239570PHASE4recruiting

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

125 enrolled

NCT06852391PHASE4recruiting

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

74 enrolled

NCT07010432PHASE1recruiting

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

144 enrolled

NCT06989203NArecruiting

Protein Supplementation Intervention on Body Weight

140 enrolled

NCT06989177NArecruiting

Probiotic Intervention on Body Weight

140 enrolled

NCT07011667PHASE3active not recruiting

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

609 enrolled

NCT07293325NArecruiting

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

66 enrolled

NCT06982859PHASE1recruiting

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

95 enrolled

NCT06639464PHASE2recruiting

Semaglutide for Helping Opioid Recovery

46 enrolled

NCT07374328PHASE1/PHASE2recruiting

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

240 enrolled

NCT06851962PHASE4active not recruiting

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

504 enrolled

NCT06884293PHASE3active not recruiting

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

479 enrolled

NCT07055607enrolling by invitation

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

1,250 enrolled

NCT07057310PHASE4enrolling by invitation

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

30 enrolled

NCT06894784PHASE3recruiting

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

36 enrolled

NCT06972992PHASE1completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

28 enrolled

NCT06499857PHASE3recruiting

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

200 enrolled

NCT06706284PHASE4recruiting

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

50 enrolled

NCT06619015PHASE2/PHASE3withdrawn

Tailoring Obesity Treatment Trial

0 enrolled

NCT06738979PHASE3not yet recruiting

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

408 enrolled

NCT06745284PHASE1active not recruiting

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

64 enrolled

NCT07163624PHASE2completed

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

211 enrolled

NCT06937060PHASE3recruiting

Effect of Semaglutide in Patients With Psoriasis and Obesity

14 enrolled

NCT05829460PHASE2withdrawn

Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

0 enrolled

NCT06863363PHASE4not yet recruiting

PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults

212 enrolled

NCT05646199PHASE2/PHASE3unknown

Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

60 enrolled

NCT06788626PHASE3not yet recruiting

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

390 enrolled

NCT06814938PHASE4active not recruiting

A Study of a Novel Precision Medicine Approach For Obesity

135 enrolled

NCT06825793NAnot yet recruiting

Semaglutide's Weight Loss Effects in Obesity

56 enrolled

NCT06778967PHASE3active not recruiting

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

1,100 enrolled

NCT06780449PHASE3active not recruiting

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

400 enrolled

NCT06896981PHASE2/PHASE3recruiting

Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

30 enrolled

NCT06764056NAnot yet recruiting

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

120 enrolled

NCT06792422PHASE4recruiting

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

126 enrolled

NCT06803888PHASE4active not recruiting

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

125 enrolled

NCT06797869PHASE2active not recruiting

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

142 enrolled

NCT06762314PHASE2recruiting

Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes

105 enrolled

NCT06608433NAcompleted

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

22 enrolled

NCT06914141completed

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

28,118 enrolled

NCT06914102completed

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

58,387 enrolled

NCT06548490PHASE2recruiting

GLP-1R Agonist Treatment for Opioid Use Disorder

200 enrolled

NCT06771115PHASE2completed

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

176 enrolled

NCT06754163PHASE4active not recruiting

Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients

20 enrolled

NCT07281196completed

Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

15 enrolled

NCT06980623active not recruiting

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

26,000 enrolled

2024

NCT05670379PHASE1completed

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

24 enrolled

NCT06648031PHASE1completed

Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

148 enrolled

NCT06716307PHASE1completed

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

18 enrolled

NCT06717698PHASE2recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

465 enrolled

NCT06387199PHASE2/PHASE3recruiting

Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

26 enrolled

NCT06716216PHASE3recruiting

A Study of BGM0504 in Participants with Type 2 Diabetes

537 enrolled

NCT06534411PHASE3active not recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

1,023 enrolled

NCT06616961PHASE3not yet recruiting

Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

480 enrolled

NCT06779929completed

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

70,000 enrolled

NCT06649344PHASE3active not recruiting

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

884 enrolled

NCT06633783PHASE3not yet recruiting

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

370 enrolled

NCT06659718completed

Emulation of the SOUL Diabetes Trial in Healthcare Claims

43,650 enrolled

NCT06659679completed

Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims

26,126 enrolled

NCT06659744completed

Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

158,310 enrolled

NCT06642584PHASE1completed

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

90 enrolled

NCT06575738PHASE1recruiting

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

40 enrolled

NCT06579105PHASE2completed

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

406 enrolled

NCT05202353PHASE1recruiting

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

30 enrolled

NCT06613854PHASE4recruiting

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

90 enrolled

NCT07096063completed

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

887,132 enrolled

NCT06269120recruiting

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

470 enrolled

NCT06396416PHASE4recruiting

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

60 enrolled

NCT06604624PHASE3completed

Semaglutide in Treatment of Obesity

462 enrolled

NCT05702931PHASE4recruiting

Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

104 enrolled

NCT06571383PHASE4active not recruiting

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

500 enrolled

NCT06507475completed

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

209 enrolled

NCT06557811PHASE4not yet recruiting

Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

88 enrolled

NCT06422624PHASE1unknown

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

14 enrolled

NCT06555146NAnot yet recruiting

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

15 enrolled

NCT06577090PHASE2active not recruiting

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

136 enrolled

NCT06449625PHASE2not yet recruiting

Semaglutide in Auto-HSCT

40 enrolled

NCT06468748PHASE4withdrawn

The Effects of Semaglutide on Body Composition and Performance in Military Personnel

0 enrolled

NCT06184633PHASE4recruiting

DUTCH Weight Control in Atrial Fibrillation Study

280 enrolled

NCT06411210PHASE2recruiting

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

54 enrolled

NCT06541509PHASE1/PHASE2recruiting

Mechanisms of Semaglutide Therapy in Heart Failure Patients

10 enrolled

NCT06986993PHASE4recruiting

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

40 enrolled

NCT06082063PHASE3recruiting

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

2,000 enrolled

NCT06478550completed

A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment

304 enrolled

NCT06500429PHASE2completed

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

120 enrolled

NCT06388187PHASE3completed

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

300 enrolled

NCT06461377PHASE4recruiting

The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

50 enrolled

NCT06338553EARLY_PHASE1recruiting

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

24 enrolled

NCT06283667active not recruiting

Special Use - Results Surveillance on Long-term Use With Wegovy®

1,071 enrolled

NCT06050577PHASE2active not recruiting

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

64 enrolled

NCT06363487NAcompleted

Semaglutide and Cognition in Healthy Volunteers

70 enrolled

NCT06287307PHASE4not yet recruiting

Semaglutide 2.4mg for Low Responders After Bariatric Surgery

152 enrolled

NCT06409130PHASE2completed

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

270 enrolled

NCT06423599PHASE2/PHASE3recruiting

Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure

100 enrolled

NCT06318442NArecruiting

The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes

60 enrolled

NCT06403761PHASE1completed

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

158 enrolled

NCT06361823PHASE3unknown

Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

74 enrolled

NCT06339086PHASE3unknown

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

478 enrolled

NCT06282458PHASE2completed

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

168 enrolled

NCT06173778PHASE2recruiting

Semaglutide for Post-Smoking Cessation Weight Management

197 enrolled

NCT05822609PHASE2recruiting

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

60 enrolled

NCT06131372PHASE2completed

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

626 enrolled

NCT06390501NAcompleted

The Effect of Weekly Semaglutide Treatment on Energy Expenditure

60 enrolled

NCT06323161PHASE3completed

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

274 enrolled

NCT06323174PHASE3completed

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

189 enrolled

NCT06299098PHASE2active not recruiting

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

1,005 enrolled

NCT06003153PHASE4recruiting

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

125 enrolled

NCT06410352PHASE4recruiting

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

220 enrolled

NCT06184568PHASE3completed

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

349 enrolled

NCT06149260PHASE1unknown

Subcutaneous Semaglutide in Systemic Scleroderma

10 enrolled

NCT06289504PHASE1completed

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

34 enrolled

NCT06161844PHASE3completed

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

506 enrolled

NCT06207877PHASE1completed

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

62 enrolled

NCT05424003PHASE2recruiting

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

50 enrolled

NCT06260722PHASE3active not recruiting

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

1,250 enrolled

NCT06234111active not recruiting

Semaglutide and Physical Activity for Obesity and Multimorbidity

35 enrolled

NCT06267092PHASE1completed

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

164 enrolled

NCT06243536PHASE4unknown

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

60 enrolled

NCT06072963PHASE2recruiting

COMMETS- Combination MCI Metabolic Syndrome

80 enrolled

NCT05746039PHASE1/PHASE2recruiting

Feasibility of Semaglutide in Advanced Lung Disease

8 enrolled

NCT06083675PHASE3withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

0 enrolled

NCT06699329PHASE1completed

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

38 enrolled

NCT06221969PHASE3completed

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

1,024 enrolled

NCT05892432PHASE2completed

Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

50 enrolled

NCT05780905PHASE4recruiting

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

50 enrolled

NCT06351748completed

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

34,238 enrolled

NCT06057077PHASE1/PHASE2unknown

Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus

120 enrolled

NCT07056803completed

Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

212 enrolled

NCT06959784PHASE4enrolling by invitation

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

142 enrolled

2023

NCT07043361completed

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

5,300 enrolled

NCT06042153PHASE4active not recruiting

DIALYSIS-TIR Study

43 enrolled

NCT06131437PHASE3completed

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

809 enrolled

NCT05819853PHASE3recruiting

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

80 enrolled

NCT06629688NAcompleted

Semaglutide and Intestinal Iron Absorption

51 enrolled

NCT06060392NArecruiting

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

50 enrolled

NCT05938712PHASE2recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

20 enrolled

NCT06015893PHASE2recruiting

Semaglutide Therapy for Alcohol Reduction (STAR)

80 enrolled

NCT05788965PHASE2/PHASE3completed

Semaglutide in CFRD

8 enrolled

NCT06097390PHASE1completed

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

121 enrolled

NCT06065540PHASE3completed

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

2,734 enrolled

NCT06045221PHASE3completed

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

1,698 enrolled

NCT05813912PHASE3completed

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

148 enrolled

NCT06041217PHASE3completed

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

242 enrolled

NCT05569772PHASE3recruiting

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

252 enrolled

NCT06974825PHASE2completed

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

67 enrolled

NCT05996848PHASE3completed

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

300 enrolled

NCT05996874PHASE1completed

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

121 enrolled

NCT06256549PHASE2unknown

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

272 enrolled

NCT05984238NAactive not recruiting

A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)

32 enrolled

NCT05990374NAunknown

Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

100 enrolled

NCT05920889PHASE2completed

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

140 enrolled

NCT05897372PHASE2terminated

Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

1 enrolled

NCT06005012PHASE2unknown

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

120 enrolled

NCT05067621PHASE2active not recruiting

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

60 enrolled

NCT05950516PHASE3unknown

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

478 enrolled

NCT05891587PHASE2completed

Semaglutide Therapy for Alcohol Reduction - Tulsa

80 enrolled

NCT05726227PHASE3active not recruiting

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

210 enrolled

NCT06354101withdrawn

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

0 enrolled

NCT05877547PHASE2completed

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

381 enrolled

NCT05819138PHASE3recruiting

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

60 enrolled

NCT05891496PHASE3completed

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

23 enrolled

NCT06154486completed

Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

30 enrolled

NCT05895643PHASE2completed

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

108 enrolled

NCT05756764active not recruiting

Anti-obesity Pharmacotherapy and Inflammation

30 enrolled

NCT05209165PHASE4suspended

Semaglutide to Reduce Atrial Fibrillation Burden

132 enrolled

NCT05890976PHASE3completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

200 enrolled

NCT05702905PHASE4unknown

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

75 enrolled

NCT06475586PHASE4completed

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

30 enrolled

NCT05870462PHASE4unknown

Semaglutide and Vascular Regeneration

100 enrolled

NCT05822830PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

751 enrolled

NCT05630586PHASE2recruiting

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

380 enrolled

NCT05751226PHASE1completed

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

88 enrolled

NCT05537233PHASE2completed

ADJUnct Semaglutide Treatment in Type 1 Diabetes

115 enrolled

NCT05813925PHASE3completed

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

331 enrolled

NCT05390307NAcompleted

Obesity Treatment to Improve Diabetes

60 enrolled

NCT05786521PHASE4completed

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

20 enrolled

NCT06827002PHASE1/PHASE2active not recruiting

Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults

248 enrolled

NCT05586802PHASE3recruiting

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

150 enrolled

NCT05784402PHASE1completed

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

264 enrolled

NCT05441267PHASE4recruiting

A Study of Cardiovascular Events iN Diabetes Plus

20,000 enrolled

NCT05443568completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

155 enrolled

NCT05766709PHASE1completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

53 enrolled

NCT05669755PHASE3active not recruiting

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

7,101 enrolled

NCT05502562completed

A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India

388 enrolled

NCT05779644NAunknown

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

300 enrolled

NCT05755360completed

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

291 enrolled

NCT07272343PHASE4recruiting

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

100 enrolled

NCT05501483NArecruiting

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

60 enrolled

NCT05394519PHASE3completed

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

1,200 enrolled

NCT05419726recruiting

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

20 enrolled

NCT05716724completed

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

288 enrolled

NCT05671653PHASE1terminated

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

32 enrolled

NCT05579249PHASE4completed

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

500 enrolled

NCT05689099PHASE1completed

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

20 enrolled

NCT05646706PHASE3completed

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

1,407 enrolled

NCT05649137PHASE3completed

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

512 enrolled

NCT05597202PHASE4unknown

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

22 enrolled

2022

NCT05087342PHASE3completed

Latino Semaglutide Study

119 enrolled

NCT05616052PHASE4unknown

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

80 enrolled

NCT05768945completed

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

742,670 enrolled

NCT05616013PHASE2completed

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

507 enrolled

NCT05073835PHASE3active not recruiting

Semaglutide 2.4 mg in Patients With Poor Weight-loss

70 enrolled

NCT05567796PHASE3active not recruiting

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

3,400 enrolled

NCT04885634PHASE3withdrawn

Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

0 enrolled

NCT05195944PHASE4enrolling by invitation

Semaglutide vs Sitagliptin

58 enrolled

NCT05443191completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

50 enrolled

NCT05254314PHASE2recruiting

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

100 enrolled

NCT05564117PHASE3completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

307 enrolled

NCT05530577PHASE2completed

Effects of Semaglutide on Nicotine Intake

24 enrolled

NCT05444153PHASE3withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

0 enrolled

NCT05473286withdrawn

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice

0 enrolled

NCT05371496PHASE2enrolling by invitation

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

81 enrolled

NCT06027567PHASE4completed

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

38 enrolled

NCT05520775PHASE2completed

Semaglutide for Alcohol Use Disorder

48 enrolled

NCT05340868NArecruiting

Genetics of the Acute Response to Oral Semaglutide

1,000 enrolled

NCT05302596PHASE2completed

Semaglutide Use in Elderly Obese Patients

16 enrolled

NCT05514535PHASE3completed

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

573 enrolled

NCT04998136PHASE3completed

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

150 enrolled

NCT05498610PHASE1completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

24 enrolled

NCT05486065PHASE2completed

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

245 enrolled

NCT05478252PHASE3completed

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

388 enrolled

NCT05443334completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

465 enrolled

NCT05548647PHASE4completed

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

120 enrolled

NCT05816057PHASE3completed

A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

476 enrolled

NCT05305794PHASE3recruiting

Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

76 enrolled

NCT05442450PHASE4unknown

Efficacy of Oral Semaglutide in Overweight or Obesity

116 enrolled

NCT05468632completed

A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

314 enrolled

NCT05435677PHASE1completed

A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together

20 enrolled

NCT05429593PHASE1completed

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

152 enrolled

NCT04174755NArecruiting

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

80 enrolled

NCT05574439PHASE4completed

Young Adults With Early-onset Obesity Treated With Semaglutide

246 enrolled

NCT05333003NAactive not recruiting

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

92 enrolled

NCT05147896NAunknown

Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

100 enrolled

NCT05533632PHASE4completed

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

104 enrolled

NCT05230589completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice

194 enrolled

NCT05259033PHASE3completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

683 enrolled

NCT05071898PHASE1recruiting

Pharmacogenetics of Response to GLP1R Agonists

600 enrolled

NCT05316662completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

187 enrolled

NCT05230615completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

458 enrolled

NCT04873245PHASE2active not recruiting

Lifestyle Counseling and Medication for Adolescent Weight Management

120 enrolled

NCT04889183PHASE3completed

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

125 enrolled

NCT05249881EARLY_PHASE1unknown

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

300 enrolled

NCT05303857PHASE4completed

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

107 enrolled

NCT06301191unknown

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

50 enrolled

NCT04854083PHASE4unknown

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

50 enrolled

NCT07457424active not recruiting

Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)

140 enrolled

NCT05236517PHASE1completed

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

60 enrolled

NCT05227196PHASE1completed

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

546 enrolled

NCT04938388PHASE4terminated

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

12 enrolled

NCT05078255NAcompleted

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

61 enrolled

NCT05232708PHASE1completed

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

18 enrolled

NCT04873050PHASE4recruiting

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

102 enrolled

NCT06118203completed

Semaglutide Use in Acute Pulmonary Embolism

18 enrolled

NCT04979130PHASE4completed

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

69 enrolled

NCT05193578PHASE2completed

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

154 enrolled

2021

NCT05857085PHASE4completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

90 enrolled

NCT05153564PHASE1completed

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

27 enrolled

NCT05173714PHASE2recruiting

Sit Less, Interact and Move More (SLIMM) 2 Study

156 enrolled

NCT05071417PHASE3unknown

Effect Of Semaglutide In Coronary Atheroma Plaque

120 enrolled

NCT05144984PHASE2completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

500 enrolled

NCT05119179PHASE4recruiting

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

300 enrolled

NCT05132088PHASE3completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

201 enrolled

NCT05129891PHASE1completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

384 enrolled

NCT04466345PHASE2completed

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

72 enrolled

NCT05064735PHASE3completed

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

407 enrolled

NCT05606471PHASE4unknown

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

45 enrolled

NCT05035095PHASE3completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

667 enrolled

NCT04615871PHASE2unknown

Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

400 enrolled

NCT04817644PHASE1completed

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

14 enrolled

NCT05046873PHASE1completed

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

16 enrolled

NCT05040971PHASE3completed

Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

207 enrolled

NCT05035082PHASE4completed

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

1,020 enrolled

NCT04892199PHASE4active not recruiting

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

104 enrolled

NCT05016882PHASE2completed

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

698 enrolled

NCT04624672PHASE4terminated

Treatment of GLP-1 for Diabetic Bariatric Patients

3 enrolled

NCT04971785PHASE2completed

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

457 enrolled

NCT04944992PHASE2completed

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

145 enrolled

NCT04982575PHASE2completed

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

92 enrolled

NCT04741074PHASE3terminated

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

15 enrolled

NCT04969939PHASE2completed

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

120 enrolled

NCT04940078PHASE1completed

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

40 enrolled

NCT05577728completed

Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

2,316 enrolled

NCT04916470PHASE3completed

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

617 enrolled

NCT04865744PHASE4completed

The Effect of Semaglutide on Pituitary Function

10 enrolled

NCT04878406PHASE1completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

24 enrolled

NCT04777409PHASE3completed

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

1,840 enrolled

NCT04777396PHASE3completed

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

1,840 enrolled

NCT04862923completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice

336 enrolled

NCT04878393completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice

650 enrolled

NCT04865770PHASE3completed

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

106 enrolled

NCT04822181PHASE3active not recruiting

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

1,205 enrolled

NCT04639414PHASE4active not recruiting

Combined Active Treatment in Type 2 Diabetes with NASH

192 enrolled

NCT04788511PHASE3completed

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

529 enrolled

NCT04216589PHASE2completed

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

51 enrolled

NCT04779697PHASE1completed

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

96 enrolled

NCT04538352PHASE4completed

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

60 enrolled

NCT04707469PHASE3completed

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

1,606 enrolled

2020

NCT04251156PHASE3completed

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

375 enrolled

NCT04601740completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

145 enrolled

NCT04601753completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice

194 enrolled

NCT04596631PHASE3completed

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

132 enrolled

NCT04559815completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

194 enrolled

NCT04560998PHASE3completed

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

792 enrolled

NCT04524832PHASE1completed

Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People

290 enrolled

NCT06489457PHASE3completed

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

25 enrolled

NCT04451837PHASE2active not recruiting

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

200 enrolled

NCT04515849PHASE2completed

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

248 enrolled

NCT04513704PHASE1completed

A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times

156 enrolled

NCT04537637completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice

99 enrolled

NCT04537624completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice

194 enrolled

NCT04469855completed

Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

3,217 enrolled

NCT04153929PHASE2completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

413 enrolled

NCT04287179PHASE3withdrawn

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

0 enrolled

NCT04447859PHASE3unknown

16-week Flexible vs. 8-week Semaglutide Titration

100 enrolled

NCT04259801PHASE1completed

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

152 enrolled

NCT04261933completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)

789 enrolled

NCT04238962PHASE1completed

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

111 enrolled

NCT04228354PHASE1completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

28 enrolled

NCT04175665completed

Real-world Health Outcomes in Canadian Patients Using Semaglutide

1,133 enrolled

2019

NCT04187300PHASE1completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

68 enrolled

NCT04383197NAunknown

Exercise and GLP-1 RA on Insulin Secretion

30 enrolled

NCT04189848PHASE4completed

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

104 enrolled

NCT04152915PHASE1completed

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

68 enrolled

NCT04263415PHASE4completed

The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

30 enrolled

NCT04061200PHASE4unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

80 enrolled

NCT04094415completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

581 enrolled

NCT04143945PHASE2completed

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

104 enrolled

NCT04016974PHASE1completed

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

32 enrolled

NCT04102189PHASE3completed

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

201 enrolled

NCT04109508PHASE1completed

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

278 enrolled

NCT04109547PHASE3completed

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

521 enrolled

NCT04097600PHASE1completed

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets

274 enrolled

NCT04083820completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

521 enrolled

NCT04074161PHASE3completed

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

338 enrolled

NCT04032197PHASE1completed

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

101 enrolled

NCT04067999completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

230 enrolled

NCT04126603PHASE4completed

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

10 enrolled

NCT03987919PHASE3completed

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

1,879 enrolled

NCT03987074PHASE2completed

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

109 enrolled

NCT04017832PHASE3completed

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

1,441 enrolled

NCT03884075PHASE2recruiting

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

84 enrolled

NCT04012255PHASE1terminated

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

29 enrolled

NCT03951753PHASE1completed

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

117 enrolled

NCT04007107PHASE2completed

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

103 enrolled

NCT03989232PHASE3completed

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

961 enrolled

NCT03987451PHASE2completed

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

71 enrolled

NCT03819153PHASE3completed

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

3,533 enrolled

NCT03914326PHASE3completed

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

9,651 enrolled

NCT03929679completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

218 enrolled

NCT04019197PHASE2active not recruiting

Effects of Semaglutide in HIV-Associated Lipohypertrophy

108 enrolled

NCT03811561PHASE3active not recruiting

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

1,500 enrolled

NCT03919929PHASE2/PHASE3completed

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

60 enrolled

NCT03876015completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

215 enrolled

NCT03899402PHASE2/PHASE3active not recruiting

Triple Therapy in T1DM

78 enrolled

NCT03985384PHASE4completed

Semaglutide Treatment On Coronary Progression

140 enrolled

NCT03842202PHASE1completed

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

72 enrolled

NCT03811574PHASE3completed

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

401 enrolled

NCT03789578PHASE1completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

30 enrolled

NCT03659682PHASE2unknown

GLP1R in Parkinson's Disease

120 enrolled

2018

NCT03574597PHASE3completed

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

17,604 enrolled

NCT03724981PHASE4completed

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

312 enrolled

NCT03292315PHASE4completed

Once Weekly GLP-1 in Persons With Spinal Cord Injury

5 enrolled

NCT03707990PHASE1completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

88 enrolled

NCT03693430PHASE3completed

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

304 enrolled

NCT03689374PHASE3completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

2,274 enrolled

NCT03631186completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

215 enrolled

NCT03648281completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

333 enrolled

NCT03638778PHASE1completed

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

105 enrolled

NCT03611322PHASE1completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

54 enrolled

NCT03611582PHASE3completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

611 enrolled

NCT03600480PHASE1completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

96 enrolled

NCT03598621PHASE1completed

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

68 enrolled

NCT03596450PHASE4completed

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

1,278 enrolled

NCT03574584PHASE1completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

37 enrolled

NCT03548935PHASE3completed

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

1,961 enrolled

NCT03552757PHASE3completed

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

1,210 enrolled

NCT03548987PHASE3completed

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

902 enrolled

NCT03457012completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

462 enrolled

NCT03466567PHASE1completed

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

21 enrolled

2017

NCT03357380PHASE1completed

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

67 enrolled

NCT03288740PHASE1completed

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

36 enrolled

NCT03061214PHASE3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

868 enrolled

NCT03191396PHASE3completed

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

577 enrolled

NCT03136484PHASE3completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

788 enrolled

NCT03086330PHASE3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

302 enrolled

NCT03021187PHASE3completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

731 enrolled

NCT02692716PHASE3completed

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

3,183 enrolled

NCT03018028PHASE3completed

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

243 enrolled

NCT03015220PHASE3completed

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

458 enrolled

NCT03010475PHASE1completed

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

41 enrolled

2016

NCT02970942PHASE2completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

320 enrolled

NCT02920385PHASE1completed

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

45 enrolled

NCT02849080PHASE3completed

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

504 enrolled

NCT02906930PHASE3completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

703 enrolled

NCT02827708PHASE3completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

324 enrolled

NCT02877355PHASE1completed

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

55 enrolled

NCT02863328PHASE3completed

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

822 enrolled

NCT02863419PHASE3completed

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

711 enrolled

NCT02845219PHASE1completed

A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

25 enrolled

NCT02773381PHASE1completed

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

15 enrolled

NCT02607865PHASE3completed

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

1,864 enrolled

NCT02648204PHASE3completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

1,201 enrolled

2015

NCT02453711PHASE2completed

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

957 enrolled

NCT02557620PHASE1completed

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

113 enrolled

NCT02461589PHASE2completed

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

706 enrolled

2014

NCT02305381PHASE3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

397 enrolled

NCT02254291PHASE3completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

308 enrolled

NCT02231684PHASE1completed

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

42 enrolled

NCT02249871PHASE1completed

Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

54 enrolled

NCT02249910PHASE1completed

Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

32 enrolled

NCT02243098PHASE1completed

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

31 enrolled

NCT02212067PHASE1completed

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

87 enrolled

NCT02210871PHASE1completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

44 enrolled

NCT02128932PHASE3completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

1,089 enrolled

NCT02207374PHASE3completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

601 enrolled

NCT02172313PHASE1completed

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

78 enrolled

NCT02161588PHASE1completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

48 enrolled

NCT02147431PHASE1completed

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

38 enrolled

NCT02146079PHASE1completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

44 enrolled

NCT02079870PHASE1completed

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

30 enrolled

NCT02070510PHASE1completed

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

52 enrolled

NCT02064348PHASE1completed

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

168 enrolled

NCT02060266PHASE1completed

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

7 enrolled

NCT02054897PHASE3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

388 enrolled

2013

NCT02022254PHASE1completed

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

24 enrolled

NCT02016911PHASE1completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

56 enrolled

NCT02014259PHASE1completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

71 enrolled

NCT01885208PHASE3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

813 enrolled

NCT01930188PHASE3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

1,231 enrolled

NCT01923181PHASE2completed

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

632 enrolled

NCT01866748PHASE1completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

170 enrolled

NCT01720446PHASE3completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

3,297 enrolled

2012

NCT01766245PHASE1completed

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

28 enrolled

NCT01686945PHASE1completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

107 enrolled

NCT01619345PHASE1completed

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

27 enrolled

NCT01572753PHASE1completed

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

161 enrolled

2011

NCT01324505PHASE1completed

Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes

43 enrolled

NCT01272973PHASE1completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

96 enrolled

2009

NCT00851773PHASE1completed

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

84 enrolled

NCT00833716PHASE1completed

Effect of Renal Impairment on the Pharmacokinetics of NN9535

62 enrolled

NCT00813020PHASE1completed

A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

44 enrolled

2008

NCT00696657PHASE2completed

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

415 enrolled

2007

NCT03144271PHASE1completed

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

58 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Diabetes Mellitus, Type 2	NCT07282613	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes	not yet recruiting	PHASE3	80
	NCT07400107	AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	not yet recruiting	PHASE3	1,000
	NCT07428746	Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes	not yet recruiting	PHASE3	20
	NCT07415954	A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes	recruiting	PHASE2	270
	NCT05689372	Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	enrolling by invitation	N/A	600
	NCT07172867	A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM	withdrawn	PHASE2	0
	NCT05714683	Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	not yet recruiting	N/A	600
	NCT07059377	Semaglutide for Smoking Cessation in Patients With Diabetes	recruiting	PHASE3	100
	NCT06797869	A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy	active not recruiting	PHASE2	142
	NCT06914141	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	completed	N/A	28,118
	NCT06914102	Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data	completed	N/A	58,387
	NCT06534411	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	active not recruiting	PHASE3	1,023
	NCT06659718	Emulation of the SOUL Diabetes Trial in Healthcare Claims	completed	N/A	43,650
	NCT06659679	Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims	completed	N/A	26,126
	NCT06659744	Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims	completed	N/A	158,310
	NCT06579105	Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.	completed	PHASE2	406
	NCT06507475	Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes	completed	N/A	209
	NCT06422624	A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects	unknown	PHASE1	14
	NCT06555146	Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy	not yet recruiting	NA	15
	NCT06478550	A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment	completed	N/A	304
	NCT06403761	Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes	completed	PHASE1	158
	NCT06260722	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	active not recruiting	PHASE3	1,250
	NCT06083675	Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes	withdrawn	PHASE3	0
	NCT05780905	Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes	recruiting	PHASE4	50
	NCT06351748	Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)	completed	N/A	34,238
	NCT05813912	A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes	completed	PHASE3	148
	NCT05984238	A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)	active not recruiting	NA	32
	NCT05870462	Semaglutide and Vascular Regeneration	unknown	PHASE4	100
	NCT05786521	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults	completed	PHASE4	20
	NCT05441267	A Study of Cardiovascular Events iN Diabetes Plus	recruiting	PHASE4	20,000
	NCT05443568	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice	completed	N/A	155
	NCT05502562	A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India	completed	N/A	388
	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
	NCT05755360	DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy	completed	N/A	291
	NCT05716724	O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait	completed	N/A	288
	NCT05689099	A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose	completed	PHASE1	20
	NCT05649137	A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight	completed	PHASE3	512
	NCT05443191	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice	completed	N/A	50
	NCT05444153	Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity	withdrawn	PHASE3	0
	NCT05473286	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice	withdrawn	N/A	0
	NCT05514535	A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)	completed	PHASE3	573
	NCT05498610	A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men	completed	PHASE1	24
	NCT05486065	A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight	completed	PHASE2	245
	NCT05478252	A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes	completed	PHASE3	388
	NCT05443334	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	completed	N/A	465
	NCT05816057	A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus	completed	PHASE3	476
	NCT05468632	A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)	completed	N/A	314
	NCT05435677	A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together	completed	PHASE1	20
	NCT05147896	Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients	unknown	NA	100
	NCT05533632	Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes	completed	PHASE4	104
	NCT05230589	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice	completed	N/A	194
	NCT05259033	A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)	completed	PHASE3	683
	NCT05316662	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice	completed	N/A	187
	NCT05230615	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	completed	N/A	458
	NCT05249881	"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."	unknown	EARLY_PHASE1	300
	NCT05303857	Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes	completed	PHASE4	107
	NCT04938388	Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care	terminated	PHASE4	12
	NCT05153564	A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause	completed	PHASE1	27
	NCT05144984	A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes	completed	PHASE2	500
	NCT04817644	A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets	completed	PHASE1	14
	NCT05046873	A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People	completed	PHASE1	16
	NCT05035082	A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)	completed	PHASE4	1,020
	NCT04624672	Treatment of GLP-1 for Diabetic Bariatric Patients	terminated	PHASE4	3
	NCT04982575	Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes	completed	PHASE2	92
	NCT05577728	Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data	completed	N/A	2,316
	NCT04862923	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice	completed	N/A	336
	NCT04878393	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice	completed	N/A	650
	NCT04865770	A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)	completed	PHASE3	106
	NCT04707469	Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes	completed	PHASE3	1,606
	NCT04251156	Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.	completed	PHASE3	375
	NCT04601740	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice	completed	N/A	145
	NCT04601753	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice	completed	N/A	194
	NCT04596631	A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	completed	PHASE3	132
	NCT04559815	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice	completed	N/A	194
	NCT04560998	A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes	completed	PHASE3	792
	NCT04524832	Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People	completed	PHASE1	290
	NCT04537637	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice	completed	N/A	99
	NCT04537624	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice	completed	N/A	194
	NCT04469855	Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®	completed	N/A	3,217
	NCT04153929	A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.	completed	PHASE2	413
	NCT04287179	SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	withdrawn	PHASE3	0
	NCT04259801	First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes	completed	PHASE1	152
	NCT04261933	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)	completed	N/A	789
	NCT04189848	Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc	completed	PHASE4	104
	NCT04152915	A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens	completed	PHASE1	68
	NCT04094415	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	completed	N/A	581
	NCT04016974	A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese	completed	PHASE1	32
	NCT04109547	A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes	completed	PHASE3	521
	NCT04083820	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)	completed	N/A	521
	NCT04032197	A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes	completed	PHASE1	101
	NCT04067999	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	completed	N/A	230
	NCT04126603	Impact of Semaglutide on CD34+ EPC and Fat Derived MSC	completed	PHASE4	10
	NCT04017832	A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes	completed	PHASE3	1,441
	NCT03951753	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	completed	PHASE1	117
	NCT03989232	A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	completed	PHASE3	961
	NCT03819153	A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease	completed	PHASE3	3,533
	NCT03914326	A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes	completed	PHASE3	9,651
	NCT03929679	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)	completed	N/A	218
	NCT03811561	A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes	active not recruiting	PHASE3	1,500
	NCT03876015	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)	completed	N/A	215
	NCT03789578	A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together	completed	PHASE1	30
	NCT03724981	A Study Comparing the Dulaglutide Pen and the Semaglutide Pen	completed	PHASE4	312
	NCT03689374	A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes	completed	PHASE3	2,274
	NCT03631186	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)	completed	N/A	215
	NCT03648281	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)	completed	N/A	333
	NCT03638778	Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men	completed	PHASE1	105
	NCT03611322	A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)	completed	PHASE1	54
	NCT03598621	A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools	completed	PHASE1	68
	NCT03596450	Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial	completed	PHASE4	1,278
	NCT03457012	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice	completed	N/A	462
	NCT03466567	A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects	completed	PHASE1	21
	NCT03288740	A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects	completed	PHASE1	36
	NCT03061214	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)	completed	PHASE3	868
	NCT03191396	Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes	completed	PHASE3	577
	NCT03136484	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes	completed	PHASE3	788
	NCT03086330	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	302
	NCT03021187	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin	completed	PHASE3	731
	NCT02692716	A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE3	3,183
	NCT03018028	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	243
	NCT03015220	Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	458
	NCT02849080	Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.	completed	PHASE3	504
	NCT02906930	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only	completed	PHASE3	703
	NCT02827708	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment	completed	PHASE3	324
	NCT02877355	Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.	completed	PHASE1	55
	NCT02863328	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	822
	NCT02863419	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	711
	NCT02845219	A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females	completed	PHASE1	25
	NCT02773381	A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes	completed	PHASE1	15
	NCT02607865	Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	completed	PHASE3	1,864
	NCT02648204	Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.	completed	PHASE3	1,201
	NCT02461589	Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes	completed	PHASE2	706
	NCT02305381	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes	completed	PHASE3	397
	NCT02254291	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	308
	NCT02212067	A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes	completed	PHASE1	87
	NCT02210871	Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function	completed	PHASE1	44
	NCT02128932	Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes	completed	PHASE3	1,089
	NCT02207374	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	601
	NCT02161588	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	48
	NCT02147431	A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	completed	PHASE1	38
	NCT02146079	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	44
	NCT02054897	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes	completed	PHASE3	388
	NCT02022254	Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects	completed	PHASE1	24
	NCT02016911	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment	completed	PHASE1	56
	NCT02014259	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function	completed	PHASE1	71
	NCT01885208	Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes	completed	PHASE3	813
	NCT01930188	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes	completed	PHASE3	1,231
	NCT01923181	Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE2	632
	NCT01866748	Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects	completed	PHASE1	170
	NCT01720446	Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE3	3,297
	NCT01686945	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes	completed	PHASE1	107
	NCT01572753	Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects	completed	PHASE1	161
	NCT01324505	Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE1	43
	NCT01272973	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects	completed	PHASE1	96
	NCT00833716	Effect of Renal Impairment on the Pharmacokinetics of NN9535	completed	PHASE1	62
	NCT00813020	A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects	completed	PHASE1	44
	NCT00696657	A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	completed	PHASE2	415
	NCT03144271	Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects	completed	PHASE1	58
Obesity	NCT07411378	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.	not yet recruiting	PHASE2	164
	NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	not yet recruiting	NA	30
	NCT07564414	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	recruiting	PHASE3	2,500
	NCT07400107	AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	not yet recruiting	PHASE3	1,000
	NCT07527195	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)	recruiting	PHASE1	100
	NCT07466017	A Study of CS060380 Tablets in Patients With MASH and Obesity	recruiting	PHASE2	120
	NCT07465965	A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults	recruiting	PHASE1	60
	NCT07323134	The Effect of Semaglutide on the Intestinal Flora in Obesity	not yet recruiting	N/A	40
	NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100
	NCT07242534	Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.	recruiting	PHASE4	62
	NCT07253285	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	recruiting	PHASE3	460
	NCT07172867	A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM	withdrawn	PHASE2	0
	NCT07284979	Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	recruiting	PHASE3	1,200
	NCT07319975	Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	not yet recruiting	NA	48
	NCT07285902	A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity	active not recruiting	PHASE3	572
	NCT07055607	A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice	enrolling by invitation	N/A	1,250
	NCT07280221	WEgovy Real World Assessment of Weight Loss in Korea	enrolling by invitation	N/A	500
	NCT07225816	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	recruiting	PHASE1	75
	NCT06801015	Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions	active not recruiting	PHASE4	30
	NCT07184086	A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet	recruiting	PHASE1	80
	NCT07091500	Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity	recruiting	NA	40
	NCT07081178	A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).	terminated	N/A	100
	NCT07513168	Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults	recruiting	PHASE4	60
	NCT07073417	A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)	active not recruiting	PHASE2	163
	NCT07101939	A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)	recruiting	PHASE2	120
	NCT07010432	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism	recruiting	PHASE1	144
	NCT06989203	Protein Supplementation Intervention on Body Weight	recruiting	NA	140
	NCT06989177	Probiotic Intervention on Body Weight	recruiting	NA	140
	NCT07011667	A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term	active not recruiting	PHASE3	609
	NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	enrolling by invitation	PHASE4	30
	NCT06619015	Tailoring Obesity Treatment Trial	withdrawn	PHASE2/PHASE3	0
	NCT06738979	A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects	not yet recruiting	PHASE3	408
	NCT06745284	A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity	active not recruiting	PHASE1	64
	NCT06814938	A Study of a Novel Precision Medicine Approach For Obesity	active not recruiting	PHASE4	135
	NCT06825793	Semaglutide's Weight Loss Effects in Obesity	not yet recruiting	NA	56
	NCT06780449	A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity	active not recruiting	PHASE3	400
	NCT06896981	Semaglutide in Women With Polycystic Ovary Syndrome and Obesity	recruiting	PHASE2/PHASE3	30
	NCT06764056	Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)	not yet recruiting	NA	120
	NCT06771115	Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity	completed	PHASE2	176
	NCT06716307	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity	completed	PHASE1	18
	NCT06616961	Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus	not yet recruiting	PHASE3	480
	NCT06633783	A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®	not yet recruiting	PHASE3	370
	NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40
	NCT05202353	A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver	recruiting	PHASE1	30
	NCT06396416	Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2	recruiting	PHASE4	60
	NCT06571383	STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss	active not recruiting	PHASE4	500
	NCT06577090	Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	active not recruiting	PHASE2	136
	NCT06468748	The Effects of Semaglutide on Body Composition and Performance in Military Personnel	withdrawn	PHASE4	0
	NCT06184633	DUTCH Weight Control in Atrial Fibrillation Study	recruiting	PHASE4	280
	NCT06411210	Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment	recruiting	PHASE2	54
	NCT06541509	Mechanisms of Semaglutide Therapy in Heart Failure Patients	recruiting	PHASE1/PHASE2	10
	NCT06388187	A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight	completed	PHASE3	300
	NCT06283667	Special Use - Results Surveillance on Long-term Use With Wegovy®	active not recruiting	N/A	1,071
	NCT06287307	Semaglutide 2.4mg for Low Responders After Bariatric Surgery	not yet recruiting	PHASE4	152
	NCT06423599	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	recruiting	PHASE2/PHASE3	100
	NCT06282458	Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	completed	PHASE2	168
	NCT06173778	Semaglutide for Post-Smoking Cessation Weight Management	recruiting	PHASE2	197
	NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	completed	PHASE2	626
	NCT06299098	A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation	active not recruiting	PHASE2	1,005
	NCT06184568	A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity	completed	PHASE3	349
	NCT06289504	A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight	completed	PHASE1	34
	NCT06207877	A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight	completed	PHASE1	62
	NCT06234111	Semaglutide and Physical Activity for Obesity and Multimorbidity	active not recruiting	N/A	35
	NCT06267092	A Study of How CagriSema Works on Appetite in People With Excess Body Weight	completed	PHASE1	164
	NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	recruiting	PHASE1/PHASE2	8
	NCT06131437	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	completed	PHASE3	809
	NCT06041217	A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range	completed	PHASE3	242
	NCT05726227	A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight	active not recruiting	PHASE3	210
	NCT05756764	Anti-obesity Pharmacotherapy and Inflammation	active not recruiting	N/A	30
	NCT05209165	Semaglutide to Reduce Atrial Fibrillation Burden	suspended	PHASE4	132
	NCT05890976	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	completed	PHASE3	200
	NCT05870462	Semaglutide and Vascular Regeneration	unknown	PHASE4	100
	NCT05822830	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	completed	PHASE3	751
	NCT05751226	A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906	completed	PHASE1	88
	NCT05537233	ADJUnct Semaglutide Treatment in Type 1 Diabetes	completed	PHASE2	115
	NCT05394519	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight	completed	PHASE3	1,200
	NCT05419726	Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.	recruiting	N/A	20
	NCT05671653	A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range	terminated	PHASE1	32
	NCT05579249	A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America	completed	PHASE4	500
	NCT05646706	A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)	completed	PHASE3	1,407
	NCT05649137	A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight	completed	PHASE3	512
	NCT05087342	Latino Semaglutide Study	completed	PHASE3	119
	NCT05616013	Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese	completed	PHASE2	507
	NCT05073835	Semaglutide 2.4 mg in Patients With Poor Weight-loss	active not recruiting	PHASE3	70
	NCT05567796	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	active not recruiting	PHASE3	3,400
	NCT05564117	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range	completed	PHASE3	307
	NCT05371496	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	enrolling by invitation	PHASE2	81
	NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38
	NCT05340868	Genetics of the Acute Response to Oral Semaglutide	recruiting	NA	1,000
	NCT05302596	Semaglutide Use in Elderly Obese Patients	completed	PHASE2	16
	NCT05514535	A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)	completed	PHASE3	573
	NCT04998136	Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity	completed	PHASE3	150
	NCT05548647	Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects	completed	PHASE4	120
	NCT05442450	Efficacy of Oral Semaglutide in Overweight or Obesity	unknown	PHASE4	116
	NCT04174755	Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV	recruiting	NA	80
	NCT05071898	Pharmacogenetics of Response to GLP1R Agonists	recruiting	PHASE1	600
	NCT04889183	SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes	completed	PHASE3	125
	NCT05236517	A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity	completed	PHASE1	60
	NCT05078255	The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes	completed	NA	61
	NCT05173714	Sit Less, Interact and Move More (SLIMM) 2 Study	recruiting	PHASE2	156
	NCT05064735	Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis	completed	PHASE3	407
	NCT05035095	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)	completed	PHASE3	667
	NCT05040971	Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes	completed	PHASE3	207
	NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	terminated	PHASE3	15
	NCT04969939	A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity	completed	PHASE2	120
	NCT04788511	Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity	completed	PHASE3	529
	NCT04779697	GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight	completed	PHASE1	96
	NCT04251156	Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.	completed	PHASE3	375
	NCT06489457	The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity	completed	PHASE3	25
	NCT04259801	First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes	completed	PHASE1	152
	NCT04238962	A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens	completed	PHASE1	111
	NCT04228354	A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide	completed	PHASE1	28
	NCT04187300	A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	completed	PHASE1	68
	NCT04189848	Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc	completed	PHASE4	104
	NCT04102189	A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity	completed	PHASE3	201
	NCT04074161	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity	completed	PHASE3	338
	NCT04012255	A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	terminated	PHASE1	29
	NCT04019197	Effects of Semaglutide in HIV-Associated Lipohypertrophy	active not recruiting	PHASE2	108
	NCT03842202	A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity	completed	PHASE1	72
	NCT03811574	STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity	completed	PHASE3	401
	NCT03574597	Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity	completed	PHASE3	17,604
	NCT03292315	Once Weekly GLP-1 in Persons With Spinal Cord Injury	completed	PHASE4	5
	NCT03693430	Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	304
	NCT03611582	Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program	completed	PHASE3	611
	NCT03600480	A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese	completed	PHASE1	96
	NCT03552757	Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity	completed	PHASE3	1,210
	NCT03548987	Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	902
	NCT02453711	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus	completed	PHASE2	957
	NCT02079870	Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo	completed	PHASE1	30
Diabetes	NCT07017270	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	not yet recruiting	PHASE4	100
	NCT06762314	Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	recruiting	PHASE2	105
	NCT05702931	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation	recruiting	PHASE4	104
	NCT05990374	Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years	unknown	NA	100
	NCT05768945	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors	completed	N/A	742,670
	NCT05073835	Semaglutide 2.4 mg in Patients With Poor Weight-loss	active not recruiting	PHASE3	70
	NCT03466567	A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects	completed	PHASE1	21
	NCT03288740	A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects	completed	PHASE1	36
	NCT03061214	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)	completed	PHASE3	868
	NCT03191396	Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes	completed	PHASE3	577
	NCT03136484	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes	completed	PHASE3	788
	NCT03086330	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	302
	NCT03021187	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin	completed	PHASE3	731
	NCT02692716	A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE3	3,183
	NCT03018028	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	243
	NCT03015220	Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	458
	NCT03010475	A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects	completed	PHASE1	41
	NCT02920385	A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.	completed	PHASE1	45
	NCT02849080	Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.	completed	PHASE3	504
	NCT02906930	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only	completed	PHASE3	703
	NCT02827708	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment	completed	PHASE3	324
	NCT02877355	Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.	completed	PHASE1	55
	NCT02863328	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	822
	NCT02863419	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	711
	NCT02845219	A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females	completed	PHASE1	25
	NCT02773381	A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes	completed	PHASE1	15
	NCT02607865	Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	completed	PHASE3	1,864
	NCT02648204	Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.	completed	PHASE3	1,201
	NCT02557620	Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly	completed	PHASE1	113
	NCT02461589	Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes	completed	PHASE2	706
	NCT02305381	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes	completed	PHASE3	397
	NCT02254291	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	308
	NCT02231684	Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide	completed	PHASE1	42
	NCT02249871	Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	completed	PHASE1	54
	NCT02249910	Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects	completed	PHASE1	32
	NCT02243098	Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects	completed	PHASE1	31
	NCT02212067	A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes	completed	PHASE1	87
	NCT02210871	Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function	completed	PHASE1	44
	NCT02128932	Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes	completed	PHASE3	1,089
	NCT02207374	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	601
	NCT02172313	Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	completed	PHASE1	78
	NCT02161588	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	48
	NCT02147431	A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	completed	PHASE1	38
	NCT02146079	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	44
	NCT02079870	Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo	completed	PHASE1	30
	NCT02070510	A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects	completed	PHASE1	52
	NCT02064348	A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects	completed	PHASE1	168
	NCT02060266	Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects	completed	PHASE1	7
	NCT02054897	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes	completed	PHASE3	388
	NCT02022254	Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects	completed	PHASE1	24
	NCT02016911	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment	completed	PHASE1	56
	NCT02014259	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function	completed	PHASE1	71
	NCT01885208	Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes	completed	PHASE3	813
	NCT01930188	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes	completed	PHASE3	1,231
	NCT01923181	Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE2	632
	NCT01866748	Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects	completed	PHASE1	170
	NCT01720446	Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE3	3,297
	NCT01766245	A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes	completed	PHASE1	28
	NCT01686945	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes	completed	PHASE1	107
	NCT01619345	Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects	completed	PHASE1	27
	NCT01572753	Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects	completed	PHASE1	161
	NCT01324505	Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE1	43
	NCT01272973	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects	completed	PHASE1	96
	NCT00851773	Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	84
	NCT00833716	Effect of Renal Impairment on the Pharmacokinetics of NN9535	completed	PHASE1	62
	NCT00813020	A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects	completed	PHASE1	44
	NCT00696657	A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	completed	PHASE2	415
	NCT03144271	Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects	completed	PHASE1	58
Type 2 Diabetes	NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	not yet recruiting	NA	30
	NCT07564414	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	recruiting	PHASE3	2,500
	NCT07485062	Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes	not yet recruiting	PHASE4	164
	NCT07547878	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	not yet recruiting	PHASE4	64
	NCT07424430	Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes	not yet recruiting	N/A	400
	NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000
	NCT07390110	Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)	active not recruiting	N/A	25,664
	NCT07271251	A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes	active not recruiting	PHASE3	264
	NCT07073053	The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms	not yet recruiting	PHASE4	60
	NCT07374328	Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus	recruiting	PHASE1/PHASE2	240
	NCT06706284	Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	recruiting	PHASE4	50
	NCT06980623	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	active not recruiting	N/A	26,000
	NCT06779929	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	completed	N/A	70,000
	NCT06649344	A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes	active not recruiting	PHASE3	884
	NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132
	NCT06269120	SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary	recruiting	N/A	470
	NCT06461377	The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy	recruiting	PHASE4	50
	NCT06050577	The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial	active not recruiting	PHASE2	64
	NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	completed	PHASE2	626
	NCT06323161	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	completed	PHASE3	274
	NCT06323174	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise	completed	PHASE3	189
	NCT06003153	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH	recruiting	PHASE4	125
	NCT06184568	A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity	completed	PHASE3	349
	NCT06243536	The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients	unknown	PHASE4	60
	NCT06221969	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	completed	PHASE3	1,024
	NCT06042153	DIALYSIS-TIR Study	active not recruiting	PHASE4	43
	NCT06045221	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	completed	PHASE3	1,698
	NCT06974825	A Study of BGM0504 in Chinese Patients With Type 2 Diabetes	completed	PHASE2	67
	NCT06256549	A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus	unknown	PHASE2	272
	NCT05950516	Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes	unknown	PHASE3	478
	NCT05501483	Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes	recruiting	NA	60
	NCT05597202	Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes	unknown	PHASE4	22
	NCT05227196	A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People	completed	PHASE1	546
	NCT05078255	The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes	completed	NA	61
	NCT04979130	Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)	completed	PHASE4	69
	NCT05129891	A Research Study Looking at New Protein-based Tablets in Healthy Male Participants	completed	PHASE1	384
	NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104
	NCT04639414	Combined Active Treatment in Type 2 Diabetes with NASH	active not recruiting	PHASE4	192
	NCT04538352	Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D	completed	PHASE4	60
	NCT04175665	Real-world Health Outcomes in Canadian Patients Using Semaglutide	completed	N/A	1,133
	NCT04383197	Exercise and GLP-1 RA on Insulin Secretion	unknown	NA	30
	NCT04109508	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets	completed	PHASE1	278
	NCT04097600	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets	completed	PHASE1	274
	NCT03987919	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	completed	PHASE3	1,879
	NCT03985384	Semaglutide Treatment On Coronary Progression	completed	PHASE4	140
Overweight	NCT07400107	AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	not yet recruiting	PHASE3	1,000
	NCT07465965	A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults	recruiting	PHASE1	60
	NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000
	NCT07253285	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	recruiting	PHASE3	460
	NCT06884293	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）	active not recruiting	PHASE3	479
	NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132
	NCT06173778	Semaglutide for Post-Smoking Cessation Weight Management	recruiting	PHASE2	197
	NCT06267092	A Study of How CagriSema Works on Appetite in People With Excess Body Weight	completed	PHASE1	164
	NCT06243536	The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients	unknown	PHASE4	60
	NCT06041217	A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range	completed	PHASE3	242
	NCT05209165	Semaglutide to Reduce Atrial Fibrillation Burden	suspended	PHASE4	132
	NCT05890976	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	completed	PHASE3	200
	NCT05822830	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	completed	PHASE3	751
	NCT05394519	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight	completed	PHASE3	1,200
	NCT05564117	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range	completed	PHASE3	307
	NCT05035095	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)	completed	PHASE3	667
	NCT04251156	Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.	completed	PHASE3	375
	NCT04259801	First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes	completed	PHASE1	152
	NCT04238962	A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens	completed	PHASE1	111
	NCT04228354	A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide	completed	PHASE1	28
	NCT04187300	A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	completed	PHASE1	68
	NCT04189848	Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc	completed	PHASE4	104
	NCT04102189	A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity	completed	PHASE3	201
	NCT04074161	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity	completed	PHASE3	338
	NCT04012255	A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	terminated	PHASE1	29
	NCT03842202	A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity	completed	PHASE1	72
	NCT03811574	STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity	completed	PHASE3	401
	NCT03574597	Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity	completed	PHASE3	17,604
	NCT03693430	Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	304
	NCT03611582	Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program	completed	PHASE3	611
	NCT03600480	A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese	completed	PHASE1	96
	NCT03552757	Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity	completed	PHASE3	1,210
Healthy	NCT06500429	A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist	completed	PHASE2	120
	NCT06699329	A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)	completed	PHASE1	38
	NCT05751226	A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906	completed	PHASE1	88
	NCT04865744	The Effect of Semaglutide on Pituitary Function	completed	PHASE4	10
	NCT03010475	A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects	completed	PHASE1	41
	NCT02920385	A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.	completed	PHASE1	45
	NCT02557620	Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly	completed	PHASE1	113
	NCT02231684	Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide	completed	PHASE1	42
	NCT02249871	Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	completed	PHASE1	54
	NCT02249910	Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects	completed	PHASE1	32
	NCT02243098	Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects	completed	PHASE1	31
	NCT02172313	Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	completed	PHASE1	78
	NCT02161588	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	48
	NCT02146079	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	44
	NCT02070510	A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects	completed	PHASE1	52
	NCT02064348	A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects	completed	PHASE1	168
	NCT02060266	Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects	completed	PHASE1	7
	NCT02022254	Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects	completed	PHASE1	24
	NCT02016911	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment	completed	PHASE1	56
	NCT02014259	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function	completed	PHASE1	71
	NCT01866748	Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects	completed	PHASE1	170
	NCT01766245	A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes	completed	PHASE1	28
	NCT01686945	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes	completed	PHASE1	107
	NCT01619345	Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects	completed	PHASE1	27
	NCT01572753	Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects	completed	PHASE1	161
	NCT01272973	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects	completed	PHASE1	96
	NCT00851773	Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	84
	NCT03144271	Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects	completed	PHASE1	58
Healthy Volunteers	NCT05429593	A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet	completed	PHASE1	152
	NCT05227196	A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People	completed	PHASE1	546
	NCT05129891	A Research Study Looking at New Protein-based Tablets in Healthy Male Participants	completed	PHASE1	384
	NCT04259801	First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes	completed	PHASE1	152
	NCT04228354	A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide	completed	PHASE1	28
	NCT04189848	Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc	completed	PHASE4	104
	NCT04152915	A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens	completed	PHASE1	68
	NCT04016974	A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese	completed	PHASE1	32
	NCT04109508	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets	completed	PHASE1	278
	NCT04097600	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets	completed	PHASE1	274
Weight Loss	NCT07223983	Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	recruiting	PHASE1	10
	NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100
	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
	NCT06989203	Protein Supplementation Intervention on Body Weight	recruiting	NA	140
	NCT06989177	Probiotic Intervention on Body Weight	recruiting	NA	140
	NCT06184633	DUTCH Weight Control in Atrial Fibrillation Study	recruiting	PHASE4	280
	NCT06423599	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	recruiting	PHASE2/PHASE3	100
	NCT05087342	Latino Semaglutide Study	completed	PHASE3	119
	NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38
	NCT05442450	Efficacy of Oral Semaglutide in Overweight or Obesity	unknown	PHASE4	116
Obesity & Overweight	NCT07411378	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.	not yet recruiting	PHASE2	164
	NCT07430059	Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant	not yet recruiting	PHASE1	20
	NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	not yet recruiting	PHASE4	20
	NCT07317115	Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes	recruiting	NA	20
	NCT07446998	Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	recruiting	PHASE2	200
	NCT07401992	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis	recruiting	PHASE4	62
	NCT07275697	Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study	not yet recruiting	PHASE4	200
	NCT07457424	Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)	active not recruiting	N/A	140
	NCT04940078	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity	completed	PHASE1	40
Type 2 Diabetes Mellitus	NCT07112872	A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes	active not recruiting	PHASE2	240
	NCT06339086	Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes	unknown	PHASE3	478
	NCT06161844	Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus	completed	PHASE3	506
	NCT06065540	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	completed	PHASE3	2,734
	NCT05067621	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	active not recruiting	PHASE2	60
	NCT05394519	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight	completed	PHASE3	1,200
	NCT06489457	The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity	completed	PHASE3	25
	NCT04515849	A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus	completed	PHASE2	248
Alcohol Use Disorder	NCT07218354	Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder	not yet recruiting	PHASE3	622
	NCT06546384	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease	not yet recruiting	NA	64
	NCT07223983	Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	recruiting	PHASE1	10
	NCT05892432	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)	completed	PHASE2	50
	NCT06015893	Semaglutide Therapy for Alcohol Reduction (STAR)	recruiting	PHASE2	80
	NCT05891587	Semaglutide Therapy for Alcohol Reduction - Tulsa	completed	PHASE2	80
	NCT05895643	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?	completed	PHASE2	108
	NCT05520775	Semaglutide for Alcohol Use Disorder	completed	PHASE2	48
Type 1 Diabetes	NCT06387199	Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide	recruiting	PHASE2/PHASE3	26
	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
	NCT06338553	GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab	recruiting	EARLY_PHASE1	24
	NCT05822609	Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes	recruiting	PHASE2	60
	NCT06057077	Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus	unknown	PHASE1/PHASE2	120
	NCT05537233	ADJUnct Semaglutide Treatment in Type 1 Diabetes	completed	PHASE2	115
	NCT05390307	Obesity Treatment to Improve Diabetes	completed	NA	60
Type 2 Diabetes Mellitus (T2DM)	NCT07187856	Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus	not yet recruiting	PHASE2	80
	NCT07163624	UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study	completed	PHASE2	211
	NCT06778967	A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus	active not recruiting	PHASE3	1,100
	NCT06716216	A Study of BGM0504 in Participants with Type 2 Diabetes	recruiting	PHASE3	537
	NCT06616961	Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus	not yet recruiting	PHASE3	480
	NCT06613854	Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes	recruiting	PHASE4	90
	NCT07272343	The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes	recruiting	PHASE4	100
Semaglutide	NCT06934655	Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth	not yet recruiting	PHASE3	150
	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
	NCT06149260	Subcutaneous Semaglutide in Systemic Scleroderma	unknown	PHASE1	10
	NCT05702905	Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome	unknown	PHASE4	75
	NCT07272343	The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes	recruiting	PHASE4	100
	NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30
Non-Alcoholic Fatty Liver Disease	NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	not yet recruiting	NA	30
	NCT06005012	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	unknown	PHASE2	120
	NCT05067621	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	active not recruiting	PHASE2	60
	NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381
	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
	NCT04216589	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	completed	PHASE2	51
	NCT03884075	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	recruiting	PHASE2	84
	NCT03357380	A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver	completed	PHASE1	67
Overweight or Obesity	NCT06499857	Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation	recruiting	PHASE3	200
	NCT05087342	Latino Semaglutide Study	completed	PHASE3	119
	NCT05616013	Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese	completed	PHASE2	507
	NCT03574584	A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese	completed	PHASE1	37
	NCT03548935	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	1,961
Non-alcoholic Steatohepatitis	NCT05766709	A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations	completed	PHASE1	53
	NCT05016882	Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)	completed	PHASE2	698
	NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	active not recruiting	PHASE3	1,205
	NCT03884075	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	recruiting	PHASE2	84
	NCT03987451	A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage	completed	PHASE2	71
	NCT02970942	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	completed	PHASE2	320
PreDiabetes	NCT07254572	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	recruiting	PHASE4	300
	NCT06619015	Tailoring Obesity Treatment Trial	withdrawn	PHASE2/PHASE3	0
	NCT05786521	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults	completed	PHASE4	20
	NCT05340868	Genetics of the Acute Response to Oral Semaglutide	recruiting	NA	1,000
	NCT05119179	Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes	recruiting	PHASE4	300
Overweight and Obesity	NCT05670379	Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant	completed	PHASE1	24
	NCT06500429	A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist	completed	PHASE2	120
	NCT05786521	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults	completed	PHASE4	20
	NCT04885634	Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients	withdrawn	PHASE3	0
	NCT05132088	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity	completed	PHASE3	201
Chronic Kidney Diseases	NCT07391267	Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.	not yet recruiting	NA	90
	NCT05173714	Sit Less, Interact and Move More (SLIMM) 2 Study	recruiting	PHASE2	156
	NCT04515849	A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus	completed	PHASE2	248
Healthy Participants	NCT06097390	A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III	completed	PHASE1	121
	NCT05996874	A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants	completed	PHASE1	121
	NCT05784402	A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants	completed	PHASE1	264
	NCT05689099	A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose	completed	PHASE1	20
Diabetes Mellitus	NCT06982859	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	recruiting	PHASE1	95
	NCT06387199	Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide	recruiting	PHASE2/PHASE3	26
	NCT06959784	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)	enrolling by invitation	PHASE4	142
	NCT05195944	Semaglutide vs Sitagliptin	enrolling by invitation	PHASE4	58
Cardiovascular Diseases	NCT07483801	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	not yet recruiting	PHASE4	112
	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
	NCT06959784	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)	enrolling by invitation	PHASE4	142
	NCT05870462	Semaglutide and Vascular Regeneration	unknown	PHASE4	100
Metabolism and Nutrition Disorder	NCT03548935	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	1,961
	NCT03548987	Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	902
	NCT02453711	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus	completed	PHASE2	957
	NCT02079870	Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo	completed	PHASE1	30
Diabetes Mellitus Type 2	NCT07065383	Rebalancing the Fat Content of the Heart and Muscles	recruiting	NA	60
	NCT06851962	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.	active not recruiting	PHASE4	504
	NCT07056803	Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus	completed	N/A	212
	NCT06629688	Semaglutide and Intestinal Iron Absorption	completed	NA	51
Heart Failure	NCT07390110	Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)	active not recruiting	N/A	25,664
	NCT06980623	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	active not recruiting	N/A	26,000
	NCT06541509	Mechanisms of Semaglutide Therapy in Heart Failure Patients	recruiting	PHASE1/PHASE2	10
	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
Obesity (Disorder)	NCT07317115	Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes	recruiting	NA	20
	NCT07424430	Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes	not yet recruiting	N/A	400
	NCT07294950	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	recruiting	PHASE3	98
	NCT06852391	JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity	recruiting	PHASE4	74
Nonalcoholic Steatohepatitis	NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381
	NCT04971785	Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	completed	PHASE2	457
	NCT04944992	A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)	completed	PHASE2	145
	NCT03987074	Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)	completed	PHASE2	109
Chronic Kidney Disease	NCT07547878	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	not yet recruiting	PHASE4	64
	NCT06717698	A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease	recruiting	PHASE2	465
	NCT06396416	Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2	recruiting	PHASE4	60
	NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	completed	PHASE2	626
	NCT04865770	A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)	completed	PHASE3	106
Atrial Fibrillation	NCT06499857	Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation	recruiting	PHASE3	200
	NCT06184633	DUTCH Weight Control in Atrial Fibrillation Study	recruiting	PHASE4	280
	NCT05209165	Semaglutide to Reduce Atrial Fibrillation Burden	suspended	PHASE4	132
	NCT04885634	Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients	withdrawn	PHASE3	0
NAFLD	NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	recruiting	PHASE2	50
	NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381
	NCT05195944	Semaglutide vs Sitagliptin	enrolling by invitation	PHASE4	58
	NCT03919929	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	completed	PHASE2/PHASE3	60
Diabetes Type 2	NCT06475586	Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus	completed	PHASE4	30
	NCT05071898	Pharmacogenetics of Response to GLP1R Agonists	recruiting	PHASE1	600
	NCT06301191	The Effect of Semaglutide on Cardiovascular Markers and Liver Function	unknown	N/A	50
HIV	NCT07221214	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	recruiting	PHASE2	200
	NCT07040592	Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide	recruiting	PHASE2	30
	NCT06691243	Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV	recruiting	PHASE2	40
Diabetic Kidney Disease	NCT05822609	Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes	recruiting	PHASE2	60
	NCT05897372	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study	terminated	PHASE2	1
	NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	terminated	PHASE3	15
Metabolic Syndrome	NCT06410352	Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome	recruiting	PHASE4	220
	NCT06072963	COMMETS- Combination MCI Metabolic Syndrome	recruiting	PHASE2	80
	NCT05073835	Semaglutide 2.4 mg in Patients With Poor Weight-loss	active not recruiting	PHASE3	70
Appetite Regulation	NCT07294950	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	recruiting	PHASE3	98
	NCT06619015	Tailoring Obesity Treatment Trial	withdrawn	PHASE2/PHASE3	0
	NCT06827002	Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults	active not recruiting	PHASE1/PHASE2	248
Acute Ischemic Stroke	NCT07030621	Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial	not yet recruiting	PHASE3	436
	NCT06788626	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	not yet recruiting	PHASE3	390
	NCT05630586	Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke	recruiting	PHASE2	380
Muscle Loss	NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	not yet recruiting	PHASE4	20
	NCT07101939	A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)	recruiting	PHASE2	120
	NCT06282458	Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	completed	PHASE2	168
Non-alcoholic Fatty Liver Disease	NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	not yet recruiting	NA	30
	NCT06005012	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	unknown	PHASE2	120
	NCT05067621	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	active not recruiting	PHASE2	60
	NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381
	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
	NCT04216589	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	completed	PHASE2	51
	NCT03884075	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	recruiting	PHASE2	84
	NCT03357380	A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver	completed	PHASE1	67
Obesity and Overweight	NCT06937060	Effect of Semaglutide in Patients With Psoriasis and Obesity	recruiting	PHASE3	14
	NCT06827002	Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults	active not recruiting	PHASE1/PHASE2	248
	NCT03707990	A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese	completed	PHASE1	88
Healthy Volunteers Type 2 Diabetes	NCT06642584	A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV	completed	PHASE1	90
	NCT04878406	A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men	completed	PHASE1	24
	NCT04513704	A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times	completed	PHASE1	156
Obesity, Childhood	NCT06977438	Promoting Healthy Children and Youth	not yet recruiting	PHASE4	1,020
	NCT05067621	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	active not recruiting	PHASE2	60
	NCT04873245	Lifestyle Counseling and Medication for Adolescent Weight Management	active not recruiting	PHASE2	120
Type 2 Diabetes Mellitus in Obese	NCT06005012	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	unknown	PHASE2	120
	NCT05606471	Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets	unknown	PHASE4	45
	NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	terminated	PHASE3	15
Diabetes Mellitus, Type 1	NCT07087795	A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes	active not recruiting	PHASE1	96
	NCT05819138	Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes	recruiting	PHASE3	60
	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Weight Management	NCT07505303	MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial	not yet recruiting	PHASE2	160
	NCT07073417	A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)	active not recruiting	PHASE2	163
	NCT06604624	Semaglutide in Treatment of Obesity	completed	PHASE3	462
Atrial Fibrillation (AF)	NCT07389941	Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation	not yet recruiting	PHASE4	240
	NCT07275697	Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study	not yet recruiting	PHASE4	200
Spinal Cord Injuries	NCT06706284	Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	recruiting	PHASE4	50
	NCT03292315	Once Weekly GLP-1 in Persons With Spinal Cord Injury	completed	PHASE4	5
Healthy Volunteers Diabetes Mellitus, Type 2	NCT04143945	A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	104
	NCT04007107	A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	103
Healthy Volunteers Obesity	NCT04143945	A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	104
	NCT04007107	A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	103
Nonalcoholic Fatty Liver Disease	NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381
	NCT04944992	A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)	completed	PHASE2	145
Aging	NCT05786521	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults	completed	PHASE4	20
	NCT05302596	Semaglutide Use in Elderly Obese Patients	completed	PHASE2	16
Obese	NCT05819853	Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome	recruiting	PHASE3	80
	NCT05616013	Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese	completed	PHASE2	507
Coronary Artery Disease	NCT07254572	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	recruiting	PHASE4	300
	NCT03985384	Semaglutide Treatment On Coronary Progression	completed	PHASE4	140
Healthy Volunteers Overweight	NCT04143945	A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	104
	NCT04007107	A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	103
GLP - 1	NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	not yet recruiting	PHASE4	20
	NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100
Alzheimer Disease	NCT07200622	Oral Semaglutide in Patients With Alzheimer's Disease	not yet recruiting	PHASE2	60
	NCT06072963	COMMETS- Combination MCI Metabolic Syndrome	recruiting	PHASE2	80
Obesity and Obesity-related Medical Conditions	NCT06803888	Bariatric Surgery vs. Semaglutide vs. Tirzepatide	active not recruiting	PHASE4	125
	NCT06754163	Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients	active not recruiting	PHASE4	20
T2DM	NCT07165158	The Effect of Semaglutide on Bone Health	not yet recruiting	PHASE4	150
	NCT07139548	A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes	not yet recruiting	PHASE3	600
Weight Gain	NCT07325500	Incretin Microdosing for Cardiometabolic Health in People With HIV	recruiting	PHASE2	30
	NCT06287307	Semaglutide 2.4mg for Low Responders After Bariatric Surgery	not yet recruiting	PHASE4	152
Metabolic Disease	NCT07043361	Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels	completed	N/A	5,300
	NCT07457424	Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)	active not recruiting	N/A	140
Idiopathic Intracranial Hypertension	NCT06361823	Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment	unknown	PHASE3	74
	NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38
Obesity or Overweight	NCT05996848	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight	completed	PHASE3	300
	NCT05813925	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight	completed	PHASE3	331
Liver Transplant; Complications	NCT06060392	Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus	recruiting	NA	50
	NCT05195944	Semaglutide vs Sitagliptin	enrolling by invitation	PHASE4	58
Prediabetic State	NCT05340868	Genetics of the Acute Response to Oral Semaglutide	recruiting	NA	1,000
	NCT05193578	Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes	completed	PHASE2	154
Weight Loss Trajectory	NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40
	NCT05087342	Latino Semaglutide Study	completed	PHASE3	119
Major Depressive Disorder	NCT07136714	Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity	recruiting	PHASE4	116
	NCT04466345	Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder	completed	PHASE2	72
Menopause	NCT06975111	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	recruiting	PHASE2/PHASE3	200
	NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	enrolling by invitation	PHASE4	30
Pre Diabetes	NCT04873050	Treatment to Regress to Normoglycemia in Women with a Recent History of GDM	recruiting	PHASE4	102
	NCT03292315	Once Weekly GLP-1 in Persons With Spinal Cord Injury	completed	PHASE4	5
Obesity/Therapy	NCT07021937	Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity	not yet recruiting	PHASE3	120
	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Obesity; Drug	NCT06390501	The Effect of Weekly Semaglutide Treatment on Energy Expenditure	completed	NA	60
	NCT05087342	Latino Semaglutide Study	completed	PHASE3	119
Cocaine Use Disorder	NCT07227948	Repurposing Semaglutide for the Treatment of Cocaine Use Disorder	recruiting	PHASE2	75
	NCT06691243	Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV	recruiting	PHASE2	40
Type 2 Diabetes (T2DM)	NCT07317115	Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes	recruiting	NA	20
	NCT07064486	A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia	recruiting	PHASE3	477
Polycystic Ovary Syndrome	NCT06222437	Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy	withdrawn	PHASE1	0
	NCT05646199	Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)	unknown	PHASE2/PHASE3	60
PCOS	NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30
	NCT03919929	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	completed	PHASE2/PHASE3	60
HFpEF - Heart Failure With Preserved Ejection Fraction	NCT06914141	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	completed	N/A	28,118
	NCT06914102	Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data	completed	N/A	58,387
Opioid Use Disorder	NCT06639464	Semaglutide for Helping Opioid Recovery	recruiting	PHASE2	46
	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
Cigarette Smoking	NCT06173778	Semaglutide for Post-Smoking Cessation Weight Management	recruiting	PHASE2	197
	NCT05520775	Semaglutide for Alcohol Use Disorder	completed	PHASE2	48
Adolescent Obesity	NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40
	NCT03919929	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	completed	PHASE2/PHASE3	60
Type2 Diabetes	NCT04854083	Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes	unknown	PHASE4	50
	NCT04451837	Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology	active not recruiting	PHASE2	200
Type2diabetes	NCT05670379	Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant	completed	PHASE1	24
	NCT06648031	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants	completed	PHASE1	148
Hepatobiliary Disorders	NCT03357380	A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver	completed	PHASE1	67
	NCT02970942	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	completed	PHASE2	320
Kidney Disease, Chronic	NCT07017270	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	not yet recruiting	PHASE4	100
	NCT06555146	Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy	not yet recruiting	NA	15
Nicotine Addiction	NCT07059377	Semaglutide for Smoking Cessation in Patients With Diabetes	recruiting	PHASE3	100
	NCT05530577	Effects of Semaglutide on Nicotine Intake	completed	PHASE2	24
Schizophrenia	NCT05193578	Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes	completed	PHASE2	154
	NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104
Weight Change, Body	NCT05616052	Comparison of Body Weight Change Through Different Smeglutide Administration Methods	unknown	PHASE4	80
	NCT05249881	"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."	unknown	EARLY_PHASE1	300
Atherosclerosis	NCT05870462	Semaglutide and Vascular Regeneration	unknown	PHASE4	100
	NCT05147896	Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients	unknown	NA	100
Psoriasis (PsO)	NCT07401992	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis	recruiting	PHASE4	62
	NCT06937060	Effect of Semaglutide in Patients With Psoriasis and Obesity	recruiting	PHASE3	14
Albuminuria	NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50
	NCT04889183	SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes	completed	PHASE3	125
Fibrosis, Liver	NCT06005012	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	unknown	PHASE2	120
FMD	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
FPF	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Functional Hypogonadism	NCT06489457	The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity	completed	PHASE3	25
Gastric Emptying	NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30
Genetic Predisposition	NCT06003153	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH	recruiting	PHASE4	125
Glaucoma	NCT06792422	A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma	recruiting	PHASE4	126
GLP-1	NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104
Glucagon-Like Peptide-1 Receptor Agonists	NCT07073053	The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms	not yet recruiting	PHASE4	60
Glucose Excursions	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Glucose Intolerance After a Recent History of Gestational Diabetes	NCT05569772	Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes	recruiting	PHASE3	252
Glucose Metabolism Disorders (Including Diabetes Mellitus)	NCT04938388	Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care	terminated	PHASE4	12
Glycemic Control for Diabetes Mellitus	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Hair-Pulling Disorder	NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	not yet recruiting	PHASE2	10
Hair Pulling	NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	not yet recruiting	PHASE2	10
Hair Pulling Disorder	NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	not yet recruiting	PHASE2	10
Healthy Volunteer Study	NCT06608433	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function	completed	NA	22
Healthy Volunteers (Diabetes Mellitus, Type 2)	NCT05232708	A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide	completed	PHASE1	18
Heart Failure With Preserved Ejection Fraction (HFpEF)	NCT05371496	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	enrolling by invitation	PHASE2	81
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2	NCT04916470	Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes	completed	PHASE3	617
Heart Failure With Reduced Ejection Fraction	NCT06423599	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	recruiting	PHASE2/PHASE3	100
Hepatic Impaired	NCT02210871	Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function	completed	PHASE1	44
High Blood Cholesterol Levels	NCT05129891	A Research Study Looking at New Protein-based Tablets in Healthy Male Participants	completed	PHASE1	384
HIV-1-infection	NCT04174755	Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV	recruiting	NA	80
HIV Infections	NCT04216589	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	completed	PHASE2	51
HIV/AIDS	NCT04019197	Effects of Semaglutide in HIV-Associated Lipohypertrophy	active not recruiting	PHASE2	108
HOMA-IR	NCT07446998	Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	recruiting	PHASE2	200
Homeostasis	NCT06989177	Probiotic Intervention on Body Weight	recruiting	NA	140
HPA	NCT06608433	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function	completed	NA	22
Hyperglycemia	NCT05702931	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation	recruiting	PHASE4	104
Impaired Glucose Tolerance	NCT05067621	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	active not recruiting	PHASE2	60
Incretins	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Infertility	NCT07242534	Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.	recruiting	PHASE4	62
Inflammation	NCT06449625	Semaglutide in Auto-HSCT	not yet recruiting	PHASE2	40
Insulin Resistance	NCT03292315	Once Weekly GLP-1 in Persons With Spinal Cord Injury	completed	PHASE4	5
Insulin Sensitivity	NCT06982859	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	recruiting	PHASE1	95
Insulin Sensitivity/Resistance	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Interstitial Lung Disease	NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	recruiting	PHASE1/PHASE2	8
Intestinal Mucositis	NCT06449625	Semaglutide in Auto-HSCT	not yet recruiting	PHASE2	40
Intestinal Permeability	NCT04979130	Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)	completed	PHASE4	69
Intracranial Pressure	NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38
Iron Absorption	NCT06629688	Semaglutide and Intestinal Iron Absorption	completed	NA	51
Ischemic Stroke	NCT07511543	Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy	not yet recruiting	PHASE2	100
Kidney Failure	NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000
Kidney Transplant Recipient	NCT06913023	Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus	not yet recruiting	PHASE2/PHASE3	74
Kidney Transplant Recipients	NCT05938712	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients	recruiting	PHASE2	20
Klinefelter Syndrome	NCT05586802	Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome	recruiting	PHASE3	150
Large Vessel Occlusion	NCT06788626	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	not yet recruiting	PHASE3	390
Lipidomics	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Lipohypertrophy	NCT04019197	Effects of Semaglutide in HIV-Associated Lipohypertrophy	active not recruiting	PHASE2	108
MAFLD	NCT07391267	Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.	not yet recruiting	NA	90
Menopause Hot Flashes	NCT06975111	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	recruiting	PHASE2/PHASE3	200
Menopause Related Conditions	NCT06975111	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	recruiting	PHASE2/PHASE3	200
Mental Disorder	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
Metabolic and Bariatric Surgery	NCT06934655	Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth	not yet recruiting	PHASE3	150
Metabolic Associated-dysfunction Steatohepatitis (MASH)	NCT06764056	Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)	not yet recruiting	NA	120
Metabolic Associated Fatty Liver Disease	NCT06764056	Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)	not yet recruiting	NA	120
Metabolic Diseases	NCT06003153	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH	recruiting	PHASE4	125
Metabolic Disturbance	NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)	NCT06884293	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）	active not recruiting	PHASE3	479
Metabolic Dysfunction-associated Steatohepatitis (MASH)	NCT07466017	A Study of CS060380 Tablets in Patients With MASH and Obesity	recruiting	PHASE2	120
Metabolic Health	NCT06354101	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	withdrawn	N/A	0
Metabolism and Nutrition Disorders	NCT03574584	A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese	completed	PHASE1	37
Metabolism Disorder, Glucose	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
Metabolism Disorder, Lipid	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
Metabolomics	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Metformin	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
Methamphetamine-dependence	NCT07204249	Glutide for Ending Methamphetamine	recruiting	PHASE2	162
Methamphetamine Use Disorder	NCT07509112	Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study	not yet recruiting	PHASE2	40
Mild Autonomous Cortisol Excess	NCT07361874	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	recruiting	NA	75
Mild Autonomous Cortisol Secretion (MACS)	NCT07361874	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	recruiting	NA	75
Mild Cognitive Impairment	NCT06072963	COMMETS- Combination MCI Metabolic Syndrome	recruiting	PHASE2	80
Mobility Disability	NCT07446998	Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	recruiting	PHASE2	200
Monogenic Obesity	NCT07302802	Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice	recruiting	N/A	70
Multimorbidity	NCT06234111	Semaglutide and Physical Activity for Obesity and Multimorbidity	active not recruiting	N/A	35
Muscle Wasting	NCT07411378	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.	not yet recruiting	PHASE2	164
Myocardial Injury	NCT04615871	Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	unknown	PHASE2	400
Narcotic-Related Disorders	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
NASH - Nonalcoholic Steatohepatitis	NCT05195944	Semaglutide vs Sitagliptin	enrolling by invitation	PHASE4	58
Neuroprotective Drugs	NCT06788626	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	not yet recruiting	PHASE3	390
Non-alcoholic Fatty Liver Disease (NAFLD)	NCT04639414	Combined Active Treatment in Type 2 Diabetes with NASH	active not recruiting	PHASE4	192
Non-Alcoholic Steatohepatitis	NCT05766709	A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations	completed	PHASE1	53
	NCT05016882	Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)	completed	PHASE2	698
	NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	active not recruiting	PHASE3	1,205
	NCT03884075	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	recruiting	PHASE2	84
	NCT03987451	A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage	completed	PHASE2	71
	NCT02970942	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	completed	PHASE2	320
Non-alcoholic Steatohepatitis (NASH)	NCT04639414	Combined Active Treatment in Type 2 Diabetes with NASH	active not recruiting	PHASE4	192
Non-diabetic Obesity	NCT06863363	PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults	not yet recruiting	PHASE4	212
Obesity-related Male Infertility	NCT07179120	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	not yet recruiting	PHASE2	180
Obesity in Diabetes	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Obesity Morbid	NCT06234111	Semaglutide and Physical Activity for Obesity and Multimorbidity	active not recruiting	N/A	35
Obesity, Abdominal	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
Obesity, Adolescent	NCT05574439	Young Adults With Early-onset Obesity Treated With Semaglutide	completed	PHASE4	246
Obesity, Morbid	NCT06287307	Semaglutide 2.4mg for Low Responders After Bariatric Surgery	not yet recruiting	PHASE4	152
Obesity/Overweight in Adult	NCT07150975	Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects	recruiting	PHASE3	420
Olanzapine	NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104
Open-Angle Glaucoma	NCT06792422	A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma	recruiting	PHASE4	126
Opioid	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
Opioid Abuse and Addiction	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
Osteopenia	NCT06050577	The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial	active not recruiting	PHASE2	64
Osteoporosis	NCT07165158	The Effect of Semaglutide on Bone Health	not yet recruiting	PHASE4	150
Osteoporosis Fracture	NCT07165158	The Effect of Semaglutide on Bone Health	not yet recruiting	PHASE4	150
Papilledema	NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38
Parkinson Disease	NCT03659682	GLP1R in Parkinson's Disease	unknown	PHASE2	120
PCOS (Polycystic Ovary Syndrome)	NCT05702905	Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome	unknown	PHASE4	75
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries	NCT05819853	Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome	recruiting	PHASE3	80
Pediatric Obesity	NCT06934655	Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth	not yet recruiting	PHASE3	150
Peripheral Arterial Disease	NCT04560998	A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes	completed	PHASE3	792
Pneumonia, Aspiration	NCT06154486	Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study	completed	N/A	30
Polycystic Ovary Syndrome (PCOS) Women	NCT06896981	Semaglutide in Women With Polycystic Ovary Syndrome and Obesity	recruiting	PHASE2/PHASE3	30
Postpartum Disorder	NCT04873050	Treatment to Regress to Normoglycemia in Women with a Recent History of GDM	recruiting	PHASE4	102
Prediabetes / Type 2 Diabetes	NCT07195994	A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes	recruiting	NA	90
Primary Open Angle Glaucoma (POAG)	NCT06792422	A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma	recruiting	PHASE4	126
Probiotic Intervention	NCT06989177	Probiotic Intervention on Body Weight	recruiting	NA	140
Prostate Cancer	NCT06908694	Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy	recruiting	PHASE4	20
Prostate Carcinoma	NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	recruiting	PHASE2	60
Protein Supplementation	NCT06989203	Protein Supplementation Intervention on Body Weight	recruiting	NA	140
Pseudotumor Cerebri Syndrome	NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38
Psoriasis Arthritis	NCT07251556	GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis	not yet recruiting	PHASE4	40
Psoriasis Vulgaris	NCT06475586	Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus	completed	PHASE4	30
Psychiatric Disorders	NCT06754163	Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients	active not recruiting	PHASE4	20
Pulmonary Embolism	NCT06118203	Semaglutide Use in Acute Pulmonary Embolism	completed	N/A	18
Pulmonary Hypertension	NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	recruiting	PHASE1/PHASE2	8
Recurrent Prostate Carcinoma	NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	recruiting	PHASE2	60
Renal Impairment	NCT00833716	Effect of Renal Impairment on the Pharmacokinetics of NN9535	completed	PHASE1	62
Renal Transplant Complication Primary Non-Function	NCT05702931	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation	recruiting	PHASE4	104
Sarcoidosis, Pulmonary	NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	recruiting	PHASE1/PHASE2	8
Schizo Affective Disorder	NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100
Schizophrenia Spectrum Disorders	NCT05333003	Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity	active not recruiting	NA	92
Scleroderma, Systemic	NCT06149260	Subcutaneous Semaglutide in Systemic Scleroderma	unknown	PHASE1	10
Severe Obesity	NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	terminated	PHASE3	15
SGLT 2 Inhibitors	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Skeletal Muscle	NCT07091500	Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity	recruiting	NA	40
Sleep Apnea Syndrome (OSAS)	NCT07281196	Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea	completed	N/A	15
Smoking Cigarette	NCT07221214	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	recruiting	PHASE2	200
Stage 1 Diabetes Mellitus, Type 1	NCT07430332	GLP-1 RA for Stage 1 Type 1 Diabetes	not yet recruiting	PHASE2	15
STEMI - ST Elevation Myocardial Infarction	NCT07297589	Epicardial Cardiac Fat-CT (EPIC-CT)	recruiting	PHASE3	136
Steroid-Induced Diabetes	NCT06318442	The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes	recruiting	NA	60
Steroid Induced Hyperglycemia	NCT06318442	The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes	recruiting	NA	60
Stroke	NCT05920889	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	completed	PHASE2	140
Stroke (CVA) or Transient Ischemic Attack	NCT05780905	Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes	recruiting	PHASE4	50
Stroke, Acute	NCT05920889	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	completed	PHASE2	140
Stroke, Ischemic	NCT05920889	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	completed	PHASE2	140
Subclinical Cushing's	NCT07361874	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	recruiting	NA	75
Substance-Related Disorders	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
T2DM (Type 2 Diabetes Mellitus)	NCT07314684	GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM	recruiting	PHASE4	80
Taste, Altered	NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30
Tobacco Dependence	NCT07059377	Semaglutide for Smoking Cessation in Patients With Diabetes	recruiting	PHASE3	100
Tobacco Use	NCT06986993	Impact of Semaglutide on Tobacco Use and Related Health Behaviors	recruiting	PHASE4	40
Tobacco Use Disorder	NCT05530577	Effects of Semaglutide on Nicotine Intake	completed	PHASE2	24
Tongue Tissue Transcriptome	NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30
Treatment Adherence	NCT06836284	The Evira Study: Additional Support During Obesity Treatment	recruiting	NA	40
Trichotillomania	NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	not yet recruiting	PHASE2	10
Trichotillomania (Hair-Pulling Disorder)	NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	not yet recruiting	PHASE2	10
Type 1 Diabetes Mellitus	NCT03899402	Triple Therapy in T1DM	active not recruiting	PHASE2/PHASE3	78
Type 1 Diabetes Mellitus (T1DM)	NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122
Type 2 Diabetes With Renal Manifestations	NCT04061200	Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria	unknown	PHASE4	80
Type 2 DM	NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50
Type 2 DM /Diabetic Nephropathy	NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50
Weight Change	NCT07294950	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	recruiting	PHASE3	98
Weight Reduction	NCT07513168	Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults	recruiting	PHASE4	60
Abdominal Fat	NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300
Weight, Body	NCT05087342	Latino Semaglutide Study	completed	PHASE3	119
Acute Myocardial Infarction	NCT06557811	Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction	not yet recruiting	PHASE4	88
Acute Myocardial Infarction With ST Elevation	NCT07295223	Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)	recruiting	PHASE3	44
Addiction	NCT06015893	Semaglutide Therapy for Alcohol Reduction (STAR)	recruiting	PHASE2	80
Adiposity	NCT06546384	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease	not yet recruiting	NA	64
Adrenal Insufficiency	NCT06608433	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function	completed	NA	22
Adult Obesity	NCT07505303	MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial	not yet recruiting	PHASE2	160
Adults With Simple Obesity	NCT07293325	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	recruiting	NA	66
Alcohol	NCT07221214	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	recruiting	PHASE2	200
Alcohol-related Liver Disease	NCT06409130	Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease	completed	PHASE2	270
Alcohol Abuse	NCT05895643	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?	completed	PHASE2	108
Alcohol Addiction	NCT05895643	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?	completed	PHASE2	108
Alcohol Dependence	NCT05895643	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?	completed	PHASE2	108
Alcohol Use Disorder (AUD)	NCT07040592	Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide	recruiting	PHASE2	30
Alzheimer Disease (AD)	NCT07135245	Improved Treatment and Monitoring of Alzheimer's Disease	not yet recruiting	PHASE2	180
Alzheimers Disease	NCT05891496	A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease	completed	PHASE3	23
Anesthesia	NCT06154486	Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study	completed	N/A	30
Anti-obesity Agents	NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40
Arterial Stiffness	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
ASCVD	NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000
Asthma	NCT05254314	Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)	recruiting	PHASE2	100
Atheroscleroses, Coronary	NCT05071417	Effect Of Semaglutide In Coronary Atheroma Plaque	unknown	PHASE3	120
Autonomous Cortisol Secretion (ACS)	NCT07361874	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	recruiting	NA	75
Bariatric Surgery	NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40
Bariatric Surgery Patients	NCT07223983	Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	recruiting	PHASE1	10
Biomarkers	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Bipolar I Disorder	NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100
Bipolar II Disorder	NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100
Blood Pressure Monitoring	NCT07294950	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	recruiting	PHASE3	98
Body-Weight Trajectory	NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40
Brain Diseases	NCT05920889	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	completed	PHASE2	140
Caloric Restriction	NCT07272343	The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes	recruiting	PHASE4	100
Cannabis Abuse	NCT07523633	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	recruiting	PHASE2	100
Cannabis Addiction	NCT07523633	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	recruiting	PHASE2	100
Cannabis Dependence	NCT07523633	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	recruiting	PHASE2	100
Cannabis Use Disorder	NCT07523633	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	recruiting	PHASE2	100
Cannabis Use Disorders	NCT07523633	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	recruiting	PHASE2	100
Cardiometabolic Risk Factors	NCT07513168	Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults	recruiting	PHASE4	60
Cardiomyopathy	NCT05371496	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	enrolling by invitation	PHASE2	81
Cardiovascular	NCT06975111	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	recruiting	PHASE2/PHASE3	200
Cardiovascular (CV) Risk	NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132
Cardiovascular Disease	NCT05669755	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels	active not recruiting	PHASE3	7,101
Cardiovascular Disease Prevention	NCT07221214	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	recruiting	PHASE2	200
Central Neural Response	NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30
Cerebrovascular Disease	NCT06959784	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)	enrolling by invitation	PHASE4	142
Chemically-Induced Disorders	NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200
Chemotherapeutic Toxicity	NCT06449625	Semaglutide in Auto-HSCT	not yet recruiting	PHASE2	40
Childhood Obesity	NCT06836284	The Evira Study: Additional Support During Obesity Treatment	recruiting	NA	40
Chronic Heart Failure	NCT06423599	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	recruiting	PHASE2/PHASE3	100
Chronic Inflammation	NCT04979130	Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)	completed	PHASE4	69
Chronic Kidney Disease(CKD)	NCT07239570	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	recruiting	PHASE4	125
Chronic Obstructive Pulmonary Disease	NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	recruiting	PHASE1/PHASE2	8
Chronic Weight Management	NCT06972992	A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide	completed	PHASE1	28
CKD	NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	terminated	PHASE3	15
Clozapine	NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104
Cognitive Change	NCT06363487	Semaglutide and Cognition in Healthy Volunteers	completed	NA	70
Cognitive Decline in Older Adults	NCT07485062	Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes	not yet recruiting	PHASE4	164
Coronary Arterial Disease (CAD)	NCT07073053	The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms	not yet recruiting	PHASE4	60
Cortisol Deficiency	NCT06608433	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function	completed	NA	22
Covid19	NCT04615871	Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	unknown	PHASE2	400
Cystic Fibrosis	NCT05788965	Semaglutide in CFRD	completed	PHASE2/PHASE3	8
Cystic Fibrosis-related Diabetes	NCT05788965	Semaglutide in CFRD	completed	PHASE2/PHASE3	8
Diabete Mellitus	NCT06060392	Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus	recruiting	NA	50
Diabetes (DM)	NCT07424430	Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes	not yet recruiting	N/A	400
Diabetes Mellitus - Type 2	NCT07401992	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis	recruiting	PHASE4	62
Diabetes Type 1	NCT06894784	A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes	recruiting	PHASE3	36
Diabetes type1	NCT06411210	Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment	recruiting	PHASE2	54
Diabetes type2	NCT04447859	16-week Flexible vs. 8-week Semaglutide Titration	unknown	PHASE3	100
Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)	NCT06461377	The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy	recruiting	PHASE4	50
Diabetic Patients	NCT06557811	Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction	not yet recruiting	PHASE4	88
Diabetic Peripheral Neuropathy	NCT06797869	A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy	active not recruiting	PHASE2	142
Dialysis	NCT07017270	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	not yet recruiting	PHASE4	100
Dietary Assessment	NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	not yet recruiting	PHASE4	20
Disordered Eating Behaviors	NCT06243536	The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients	unknown	PHASE4	60
Double Diabetes	NCT05305794	Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"	recruiting	PHASE3	76
Early Alzheimer's Disease	NCT04777396	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)	completed	PHASE3	1,840
Early Alzheimer´s Disease	NCT04777409	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)	completed	PHASE3	1,840
End Stage Kidney Disease (ESRD)	NCT07017270	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	not yet recruiting	PHASE4	100
End Stage Renal Disease on Dialysis	NCT06042153	DIALYSIS-TIR Study	active not recruiting	PHASE4	43
Endometrial Hyperplasia	NCT05829460	Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia	withdrawn	PHASE2	0
Endothelial Dysfunction	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Endothelial Progenitor Cells	NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90
Endovascular Treatment	NCT06788626	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	not yet recruiting	PHASE3	390
Epicardial Fat	NCT07297589	Epicardial Cardiac Fat-CT (EPIC-CT)	recruiting	PHASE3	136
Exercise Intervention	NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	not yet recruiting	PHASE4	20
Fatty Liver	NCT06546384	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease	not yet recruiting	NA	64
Fatty Liver, Nonalcoholic	NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381
Fibrosis	NCT06149260	Subcutaneous Semaglutide in Systemic Scleroderma	unknown	PHASE1	10

All Semaglutide Clinical Trials (537)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07430332	GLP-1 RA for Stage 1 Type 1 Diabetes	not yet recruiting	PHASE2	15	Children's Hospital Medical Center, Cincinnati
NCT06977438	Promoting Healthy Children and Youth	not yet recruiting	PHASE4	1,020	University of Minnesota
NCT07389941	Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation	not yet recruiting	PHASE4	240	University of Luebeck
NCT07282613	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes	not yet recruiting	PHASE3	80	Novo Nordisk A/S
NCT07411378	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.	not yet recruiting	PHASE2	164	Biophytis
NCT07218354	Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder	not yet recruiting	PHASE3	622	VA Office of Research and Development
NCT07511543	Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy	not yet recruiting	PHASE2	100	Population Health Research Institute
NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	not yet recruiting	NA	30	Shanghai Jiao Tong University School of Medicine
NCT06934655	Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth	not yet recruiting	PHASE3	150	Children's Hospital Los Angeles
NCT07509112	Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study	not yet recruiting	PHASE2	40	Kirby Institute
NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	not yet recruiting	PHASE2	10	University of Chicago
NCT07564414	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	recruiting	PHASE3	2,500	Novo Nordisk A/S
NCT07400107	AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	not yet recruiting	PHASE3	1,000	Novo Nordisk A/S
NCT06546384	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease	not yet recruiting	NA	64	Insel Gruppe AG, University Hospital Bern
NCT07021937	Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity	not yet recruiting	PHASE3	120	University of Colorado, Denver
NCT07485062	Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes	not yet recruiting	PHASE4	164	Western University, Canada
NCT07179120	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	not yet recruiting	PHASE2	180	First Affiliated Hospital of Wenzhou Medical University
NCT07523633	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	recruiting	PHASE2	100	Anders Fink-Jensen, MD, DMSci
NCT07428746	Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes	not yet recruiting	PHASE3	20	Emory University
NCT07430059	Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant	not yet recruiting	PHASE1	20	Vivani Medical, Inc
NCT07415954	A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes	recruiting	PHASE2	270	Novo Nordisk A/S
NCT07221214	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	recruiting	PHASE2	200	Vanderbilt University Medical Center
NCT07527195	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)	recruiting	PHASE1	100	Novo Nordisk A/S
NCT07547878	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	not yet recruiting	PHASE4	64	Baylor Research Institute
NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	not yet recruiting	PHASE4	20	William Marsh Rice University
NCT07466017	A Study of CS060380 Tablets in Patients With MASH and Obesity	recruiting	PHASE2	120	Cascade Pharmaceuticals, Inc
NCT07317115	Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes	recruiting	NA	20	GT Metabolic Solutions, Inc.
NCT07483801	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	not yet recruiting	PHASE4	112	Cambridge University Hospitals NHS Foundation Trust
NCT07424430	Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes	not yet recruiting	N/A	400	LMC Diabetes & Endocrinology Ltd.
NCT07223983	Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	recruiting	PHASE1	10	Yale University
NCT07446998	Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	recruiting	PHASE2	200	Veru Inc.
NCT07505303	MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial	not yet recruiting	PHASE2	160	Eccogene
NCT07361874	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	recruiting	NA	75	University of Texas Southwestern Medical Center
NCT07465965	A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults	recruiting	PHASE1	60	Shanghai World Leader Pharmaceutical Co., Ltd.
NCT06975111	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	recruiting	PHASE2/PHASE3	200	University of Colorado, Denver
NCT06222437	Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy	withdrawn	PHASE1	0	Methodist Health System
NCT06836284	The Evira Study: Additional Support During Obesity Treatment	recruiting	NA	40	Karolinska Institutet
NCT07325500	Incretin Microdosing for Cardiometabolic Health in People With HIV	recruiting	PHASE2	30	The University of Texas Health Science Center, Houston
NCT07195994	A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes	recruiting	NA	90	QuickSilver Scientific
NCT05689372	Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	enrolling by invitation	N/A	600	Novo Nordisk A/S
NCT07294950	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	recruiting	PHASE3	98	Mount Sinai Hospital, Canada
NCT07323134	The Effect of Semaglutide on the Intestinal Flora in Obesity	not yet recruiting	N/A	40	Beijing Chao Yang Hospital
NCT07391267	Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.	not yet recruiting	NA	90	Institute of Liver and Biliary Sciences, India
NCT07187856	Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus	not yet recruiting	PHASE2	80	ProGen. Co., Ltd.
NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000	Brigham and Women's Hospital
NCT07390110	Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)	active not recruiting	N/A	25,664	Brigham and Women's Hospital
NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	recruiting	PHASE2	60	City of Hope Medical Center
NCT07213466	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	recruiting	PHASE4	100	Mayo Clinic
NCT07242534	Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.	recruiting	PHASE4	62	Fundacion Dexeus
NCT07227948	Repurposing Semaglutide for the Treatment of Cocaine Use Disorder	recruiting	PHASE2	75	The University of Texas Health Science Center, Houston
NCT07401992	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis	recruiting	PHASE4	62	Hospital Universitario Dr. Jose E. Gonzalez
NCT07040592	Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide	recruiting	PHASE2	30	Yale University
NCT07204249	Glutide for Ending Methamphetamine	recruiting	PHASE2	162	San Francisco Department of Public Health
NCT07253285	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	recruiting	PHASE3	460	Novo Nordisk A/S
NCT07172867	A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM	withdrawn	PHASE2	0	Halia Therapeutics, Inc.
NCT06913023	Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus	not yet recruiting	PHASE2/PHASE3	74	University Health Network, Toronto
NCT07135245	Improved Treatment and Monitoring of Alzheimer's Disease	not yet recruiting	PHASE2	180	Rune Skovgaard Rasmussen
NCT05714683	Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	not yet recruiting	N/A	600	Novo Nordisk A/S
NCT07295223	Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)	recruiting	PHASE3	44	Instituto Mexicano del Seguro Social
NCT07284979	Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	recruiting	PHASE3	1,200	Kailera
NCT07297589	Epicardial Cardiac Fat-CT (EPIC-CT)	recruiting	PHASE3	136	Instituto Mexicano del Seguro Social
NCT07319975	Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	not yet recruiting	NA	48	Istanbul Galata University
NCT07285902	A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity	active not recruiting	PHASE3	572	Fujian Shengdi Pharmaceutical Co., Ltd.
NCT07275697	Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study	not yet recruiting	PHASE4	200	Emma Svennberg
NCT07271251	A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes	active not recruiting	PHASE3	264	Novo Nordisk A/S
NCT07251556	GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis	not yet recruiting	PHASE4	40	Chinese University of Hong Kong
NCT07302802	Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice	recruiting	N/A	70	Prof. Dr. Martin Wabitsch
NCT07055607	A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice	enrolling by invitation	N/A	1,250	Novo Nordisk A/S
NCT06954090	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	enrolling by invitation	PHASE4	50	Steno Diabetes Center Copenhagen
NCT07280221	WEgovy Real World Assessment of Weight Loss in Korea	enrolling by invitation	N/A	500	Novo Nordisk A/S
NCT07225816	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	recruiting	PHASE1	75	Novo Nordisk A/S
NCT06909006	Semaglutide Treatment in Type 1 Diabetes	not yet recruiting	PHASE3	122	Nordsjaellands Hospital
NCT07073053	The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms	not yet recruiting	PHASE4	60	Taipei Veterans General Hospital, Taiwan
NCT06801015	Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions	active not recruiting	PHASE4	30	Mayo Clinic
NCT07059377	Semaglutide for Smoking Cessation in Patients With Diabetes	recruiting	PHASE3	100	Ottawa Heart Institute Research Corporation
NCT07184086	A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet	recruiting	PHASE1	80	Novo Nordisk A/S
NCT07200622	Oral Semaglutide in Patients With Alzheimer's Disease	not yet recruiting	PHASE2	60	Imperial College London
NCT07150975	Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects	recruiting	PHASE3	420	Gan & Lee Pharmaceuticals.
NCT07165158	The Effect of Semaglutide on Bone Health	not yet recruiting	PHASE4	150	The First Affiliated Hospital of Xiamen University
NCT07136714	Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity	recruiting	PHASE4	116	Nordsjaellands Hospital
NCT07314684	GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM	recruiting	PHASE4	80	Federico II University
NCT07139548	A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes	not yet recruiting	PHASE3	600	Guangdong Raynovent Biotech Co., Ltd
NCT07112872	A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes	active not recruiting	PHASE2	240	Hoffmann-La Roche
NCT07091500	Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity	recruiting	NA	40	Washington University School of Medicine
NCT07081178	A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).	terminated	N/A	100	Novo Nordisk A/S
NCT06691243	Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV	recruiting	PHASE2	40	University of Maryland, Baltimore
NCT07065383	Rebalancing the Fat Content of the Heart and Muscles	recruiting	NA	60	University of Aberdeen
NCT07513168	Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults	recruiting	PHASE4	60	Asian Institute Of Medical Sciences
NCT07017270	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	not yet recruiting	PHASE4	100	Unity Health Toronto
NCT07073417	A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)	active not recruiting	PHASE2	163	Hangzhou Sciwind Biosciences Co., Ltd.
NCT07254572	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	recruiting	PHASE4	300	National Institute of Cardiology, Warsaw, Poland
NCT07064486	A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia	recruiting	PHASE3	477	BrightGene Bio-Medical Technology Co., Ltd.
NCT06908694	Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy	recruiting	PHASE4	20	Hamilton Health Sciences Corporation
NCT07030621	Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial	not yet recruiting	PHASE3	436	RenJi Hospital
NCT07087795	A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes	active not recruiting	PHASE1	96	Novo Nordisk A/S
NCT07101939	A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)	recruiting	PHASE2	120	Actimed Therapeutics Ltd
NCT07239570	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	recruiting	PHASE4	125	Peter Rossing
NCT06852391	JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity	recruiting	PHASE4	74	McMaster University
NCT07010432	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism	recruiting	PHASE1	144	Novo Nordisk A/S
NCT06989203	Protein Supplementation Intervention on Body Weight	recruiting	NA	140	Chinese Academy of Sciences
NCT06989177	Probiotic Intervention on Body Weight	recruiting	NA	140	Chinese Academy of Sciences
NCT07011667	A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term	active not recruiting	PHASE3	609	Novo Nordisk A/S
NCT07293325	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	recruiting	NA	66	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06982859	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	recruiting	PHASE1	95	Eli Lilly and Company
NCT06639464	Semaglutide for Helping Opioid Recovery	recruiting	PHASE2	46	Brigham and Women's Hospital
NCT07374328	Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus	recruiting	PHASE1/PHASE2	240	Second Affiliated Hospital of Guangzhou Medical University
NCT06851962	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.	active not recruiting	PHASE4	504	Fundación para la Investigación del Hospital Clínico de Valencia
NCT06884293	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）	active not recruiting	PHASE3	479	Innovent Biologics (Suzhou) Co. Ltd.
NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	enrolling by invitation	PHASE4	30	Mayo Clinic
NCT06894784	A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes	recruiting	PHASE3	36	McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT06972992	A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide	completed	PHASE1	28	Ascletis Pharma (China) Co., Limited
NCT06499857	Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation	recruiting	PHASE3	200	University of Chicago
NCT06706284	Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	recruiting	PHASE4	50	Marzieh Salehi
NCT06619015	Tailoring Obesity Treatment Trial	withdrawn	PHASE2/PHASE3	0	Esbjerg Hospital - University Hospital of Southern Denmark
NCT06738979	A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects	not yet recruiting	PHASE3	408	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06745284	A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity	active not recruiting	PHASE1	64	Boehringer Ingelheim
NCT07163624	UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study	completed	PHASE2	211	The United Bio-Technology (Hengqin) Co., Ltd.
NCT06937060	Effect of Semaglutide in Patients With Psoriasis and Obesity	recruiting	PHASE3	14	The University of Hong Kong
NCT05829460	Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia	withdrawn	PHASE2	0	Washington University School of Medicine
NCT05646199	Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)	unknown	PHASE2/PHASE3	60	University of Hull
NCT06788626	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	not yet recruiting	PHASE3	390	Wei Hu
NCT06814938	A Study of a Novel Precision Medicine Approach For Obesity	active not recruiting	PHASE4	135	Mayo Clinic
NCT06825793	Semaglutide's Weight Loss Effects in Obesity	not yet recruiting	NA	56	Beijing Chao Yang Hospital
NCT06778967	A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus	active not recruiting	PHASE3	1,100	Gan & Lee Pharmaceuticals.
NCT06780449	A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity	active not recruiting	PHASE3	400	Novo Nordisk A/S
NCT06896981	Semaglutide in Women With Polycystic Ovary Syndrome and Obesity	recruiting	PHASE2/PHASE3	30	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT06764056	Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)	not yet recruiting	NA	120	Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
NCT06792422	A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma	recruiting	PHASE4	126	Glostrup University Hospital, Copenhagen
NCT06803888	Bariatric Surgery vs. Semaglutide vs. Tirzepatide	active not recruiting	PHASE4	125	Ali Aminian
NCT06797869	A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy	active not recruiting	PHASE2	142	Novo Nordisk A/S
NCT06762314	Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	recruiting	PHASE2	105	Mostafa Bahaa
NCT06608433	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function	completed	NA	22	University Hospital, Basel, Switzerland
NCT06914141	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	completed	N/A	28,118	Brigham and Women's Hospital
NCT06914102	Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data	completed	N/A	58,387	Brigham and Women's Hospital
NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	recruiting	PHASE2	200	Milton S. Hershey Medical Center
NCT06771115	Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity	completed	PHASE2	176	Zomagen Biosciences Ltd.
NCT06754163	Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients	active not recruiting	PHASE4	20	St Andrew's Healthcare
NCT07281196	Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea	completed	N/A	15	Shanghai Fengxian District Central Hospital
NCT06980623	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	active not recruiting	N/A	26,000	Brigham and Women's Hospital
NCT05670379	Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant	completed	PHASE1	24	Vivani Medical, Inc
NCT06648031	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants	completed	PHASE1	148	Lexaria Bioscience Corp.
NCT06716307	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity	completed	PHASE1	18	Novo Nordisk A/S
NCT06717698	A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease	recruiting	PHASE2	465	Novo Nordisk A/S
NCT06387199	Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide	recruiting	PHASE2/PHASE3	26	McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT06716216	A Study of BGM0504 in Participants with Type 2 Diabetes	recruiting	PHASE3	537	BrightGene Bio-Medical Technology Co., Ltd.
NCT06534411	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	active not recruiting	PHASE3	1,023	Novo Nordisk A/S
NCT06616961	Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus	not yet recruiting	PHASE3	480	Popular Medical College Hospital
NCT06779929	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	completed	N/A	70,000	Brigham and Women's Hospital
NCT06649344	A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes	active not recruiting	PHASE3	884	Fujian Shengdi Pharmaceutical Co., Ltd.
NCT06633783	A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®	not yet recruiting	PHASE3	370	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
NCT06659718	Emulation of the SOUL Diabetes Trial in Healthcare Claims	completed	N/A	43,650	Brigham and Women's Hospital
NCT06659679	Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims	completed	N/A	26,126	Brigham and Women's Hospital
NCT06659744	Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims	completed	N/A	158,310	Brigham and Women's Hospital
NCT06642584	A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV	completed	PHASE1	90	Novo Nordisk A/S
NCT06575738	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	recruiting	PHASE1	40	University of Colorado, Denver
NCT06579105	Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.	completed	PHASE2	406	AstraZeneca
NCT05202353	A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver	recruiting	PHASE1	30	Boehringer Ingelheim
NCT06613854	Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes	recruiting	PHASE4	90	University Medical Centre Ljubljana
NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132	Brigham and Women's Hospital
NCT06269120	SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary	recruiting	N/A	470	Novo Nordisk A/S
NCT06396416	Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2	recruiting	PHASE4	60	Western University, Canada
NCT06604624	Semaglutide in Treatment of Obesity	completed	PHASE3	462	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
NCT05702931	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation	recruiting	PHASE4	104	Rigshospitalet, Denmark
NCT06571383	STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss	active not recruiting	PHASE4	500	Novo Nordisk A/S
NCT06507475	Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes	completed	N/A	209	Novo Nordisk A/S
NCT06557811	Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction	not yet recruiting	PHASE4	88	University of Sao Paulo General Hospital
NCT06422624	A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects	unknown	PHASE1	14	Bostal Drug Delivery Co., Ltd
NCT06555146	Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy	not yet recruiting	NA	15	Bispebjerg Hospital
NCT06577090	Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	active not recruiting	PHASE2	136	Skye Bioscience, Inc.
NCT06449625	Semaglutide in Auto-HSCT	not yet recruiting	PHASE2	40	Klaus Gottlob Müller
NCT06468748	The Effects of Semaglutide on Body Composition and Performance in Military Personnel	withdrawn	PHASE4	0	United States Army Research Institute of Environmental Medicine
NCT06184633	DUTCH Weight Control in Atrial Fibrillation Study	recruiting	PHASE4	280	Rijnstate Hospital
NCT06411210	Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment	recruiting	PHASE2	54	Yale University
NCT06541509	Mechanisms of Semaglutide Therapy in Heart Failure Patients	recruiting	PHASE1/PHASE2	10	University Medical Centre Ljubljana
NCT06986993	Impact of Semaglutide on Tobacco Use and Related Health Behaviors	recruiting	PHASE4	40	University of Oklahoma
NCT06082063	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	recruiting	PHASE3	2,000	Steno Diabetes Center Copenhagen
NCT06478550	A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment	completed	N/A	304	Novo Nordisk A/S
NCT06500429	A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist	completed	PHASE2	120	Neurogastrx, Inc.
NCT06388187	A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight	completed	PHASE3	300	Novo Nordisk A/S
NCT06461377	The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy	recruiting	PHASE4	50	The First Affiliated Hospital with Nanjing Medical University
NCT06338553	GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab	recruiting	EARLY_PHASE1	24	Vanderbilt University Medical Center
NCT06283667	Special Use - Results Surveillance on Long-term Use With Wegovy®	active not recruiting	N/A	1,071	Novo Nordisk A/S
NCT06050577	The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial	active not recruiting	PHASE2	64	Odense University Hospital
NCT06363487	Semaglutide and Cognition in Healthy Volunteers	completed	NA	70	University of Oxford
NCT06287307	Semaglutide 2.4mg for Low Responders After Bariatric Surgery	not yet recruiting	PHASE4	152	Zuyderland Medisch Centrum
NCT06409130	Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease	completed	PHASE2	270	Novo Nordisk A/S
NCT06423599	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	recruiting	PHASE2/PHASE3	100	Jens D Hove, MD,PHD
NCT06318442	The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes	recruiting	NA	60	Imperial College London
NCT06403761	Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes	completed	PHASE1	158	Novo Nordisk A/S
NCT06361823	Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment	unknown	PHASE3	74	Capital Medical University
NCT06339086	Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes	unknown	PHASE3	478	Chengdu Brilliant Pharmaceutical Co., Ltd.
NCT06282458	Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	completed	PHASE2	168	Veru Inc.
NCT06173778	Semaglutide for Post-Smoking Cessation Weight Management	recruiting	PHASE2	197	The University of Texas Health Science Center, Houston
NCT05822609	Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes	recruiting	PHASE2	60	University of Washington
NCT06131372	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	completed	PHASE2	626	Novo Nordisk A/S
NCT06390501	The Effect of Weekly Semaglutide Treatment on Energy Expenditure	completed	NA	60	Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
NCT06323161	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	completed	PHASE3	274	Novo Nordisk A/S
NCT06323174	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise	completed	PHASE3	189	Novo Nordisk A/S
NCT06299098	A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation	active not recruiting	PHASE2	1,005	Regeneron Pharmaceuticals
NCT06003153	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH	recruiting	PHASE4	125	Massachusetts General Hospital
NCT06410352	Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome	recruiting	PHASE4	220	University Medical Center, Kazakhstan
NCT06184568	A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity	completed	PHASE3	349	Innovent Biologics (Suzhou) Co. Ltd.
NCT06149260	Subcutaneous Semaglutide in Systemic Scleroderma	unknown	PHASE1	10	Second Xiangya Hospital of Central South University
NCT06289504	A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight	completed	PHASE1	34	Novo Nordisk A/S
NCT06161844	Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus	completed	PHASE3	506	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT06207877	A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight	completed	PHASE1	62	Novo Nordisk A/S
NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	recruiting	PHASE2	50	University of Virginia
NCT06260722	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	active not recruiting	PHASE3	1,250	Eli Lilly and Company
NCT06234111	Semaglutide and Physical Activity for Obesity and Multimorbidity	active not recruiting	N/A	35	Hvidovre University Hospital
NCT06267092	A Study of How CagriSema Works on Appetite in People With Excess Body Weight	completed	PHASE1	164	Novo Nordisk A/S
NCT06243536	The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients	unknown	PHASE4	60	University Hospital Sestre Milosrdnice
NCT06072963	COMMETS- Combination MCI Metabolic Syndrome	recruiting	PHASE2	80	Rutgers, The State University of New Jersey
NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	recruiting	PHASE1/PHASE2	8	University of Pennsylvania
NCT06083675	Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes	withdrawn	PHASE3	0	Novo Nordisk A/S
NCT06699329	A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)	completed	PHASE1	38	Merck Sharp & Dohme LLC
NCT06221969	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	completed	PHASE3	1,024	Novo Nordisk A/S
NCT05892432	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)	completed	PHASE2	50	University of Colorado, Denver
NCT05780905	Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes	recruiting	PHASE4	50	University of Washington
NCT06351748	Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)	completed	N/A	34,238	Novo Nordisk A/S
NCT06057077	Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus	unknown	PHASE1/PHASE2	120	Ministry of Health, Saudi Arabia
NCT07056803	Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus	completed	N/A	212	University of Palermo
NCT06959784	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)	enrolling by invitation	PHASE4	142	China-Japan Friendship Hospital
NCT07043361	Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels	completed	N/A	5,300	Hillel Yaffe Medical Center
NCT06042153	DIALYSIS-TIR Study	active not recruiting	PHASE4	43	University of Texas Southwestern Medical Center
NCT06131437	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	completed	PHASE3	809	Novo Nordisk A/S
NCT05819853	Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome	recruiting	PHASE3	80	University of Colorado, Denver
NCT06629688	Semaglutide and Intestinal Iron Absorption	completed	NA	51	University Hospital Dubrava
NCT06060392	Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus	recruiting	NA	50	Medanta, The Medicity, India
NCT05938712	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients	recruiting	PHASE2	20	University Health Network, Toronto
NCT06015893	Semaglutide Therapy for Alcohol Reduction (STAR)	recruiting	PHASE2	80	National Institute on Drug Abuse (NIDA)
NCT05788965	Semaglutide in CFRD	completed	PHASE2/PHASE3	8	University of Minnesota
NCT06097390	A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III	completed	PHASE1	121	Novo Nordisk A/S
NCT06065540	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	completed	PHASE3	2,734	Novo Nordisk A/S
NCT06045221	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	completed	PHASE3	1,698	Eli Lilly and Company
NCT05813912	A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes	completed	PHASE3	148	Novo Nordisk A/S
NCT06041217	A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range	completed	PHASE3	242	Novo Nordisk A/S
NCT05569772	Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes	recruiting	PHASE3	252	Universitaire Ziekenhuizen KU Leuven
NCT06974825	A Study of BGM0504 in Chinese Patients With Type 2 Diabetes	completed	PHASE2	67	BrightGene Bio-Medical Technology Co., Ltd.
NCT05996848	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight	completed	PHASE3	300	Novo Nordisk A/S
NCT05996874	A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants	completed	PHASE1	121	Novo Nordisk A/S
NCT06256549	A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus	unknown	PHASE2	272	Gan and Lee Pharmaceuticals, USA
NCT05984238	A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)	active not recruiting	NA	32	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT05990374	Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years	unknown	NA	100	Nanjing First Hospital, Nanjing Medical University
NCT05920889	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	completed	PHASE2	140	Chinese University of Hong Kong
NCT05897372	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study	terminated	PHASE2	1	Iain Bressendorff
NCT06005012	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	unknown	PHASE2	120	University of California, San Diego
NCT05067621	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	active not recruiting	PHASE2	60	Yale University
NCT05950516	Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes	unknown	PHASE3	478	Qilu Pharmaceutical Co., Ltd.
NCT05891587	Semaglutide Therapy for Alcohol Reduction - Tulsa	completed	PHASE2	80	Oklahoma State University Center for Health Sciences
NCT05726227	A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight	active not recruiting	PHASE3	210	Novo Nordisk A/S
NCT06354101	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	withdrawn	N/A	0	CorEvitas
NCT05877547	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	completed	PHASE2	381	Merck Sharp & Dohme LLC
NCT05819138	Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes	recruiting	PHASE3	60	University of Colorado, Denver
NCT05891496	A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease	completed	PHASE3	23	Novo Nordisk A/S
NCT06154486	Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study	completed	N/A	30	Hospital Israelita Albert Einstein
NCT05895643	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?	completed	PHASE2	108	Psychiatric Centre Rigshospitalet
NCT05756764	Anti-obesity Pharmacotherapy and Inflammation	active not recruiting	N/A	30	Louisiana State University Health Sciences Center in New Orleans
NCT05209165	Semaglutide to Reduce Atrial Fibrillation Burden	suspended	PHASE4	132	San Francisco Veterans Affairs Medical Center
NCT05890976	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	completed	PHASE3	200	Novo Nordisk A/S
NCT05702905	Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome	unknown	PHASE4	75	Peking University First Hospital
NCT06475586	Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus	completed	PHASE4	30	University of Banja Luka
NCT05870462	Semaglutide and Vascular Regeneration	unknown	PHASE4	100	Canadian Medical and Surgical Knowledge Translation Research Group
NCT05822830	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	completed	PHASE3	751	Eli Lilly and Company
NCT05630586	Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke	recruiting	PHASE2	380	Aarhus University Hospital
NCT05751226	A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906	completed	PHASE1	88	Boehringer Ingelheim
NCT05537233	ADJUnct Semaglutide Treatment in Type 1 Diabetes	completed	PHASE2	115	Viral N. Shah
NCT05813925	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight	completed	PHASE3	331	Novo Nordisk A/S
NCT05390307	Obesity Treatment to Improve Diabetes	completed	NA	60	Dasman Diabetes Institute
NCT05786521	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults	completed	PHASE4	20	The University of Texas Health Science Center at San Antonio
NCT05586802	Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome	recruiting	PHASE3	150	Georgios Papadakis
NCT05784402	A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants	completed	PHASE1	264	Novo Nordisk A/S
NCT05441267	A Study of Cardiovascular Events iN Diabetes Plus	recruiting	PHASE4	20,000	University of Oxford
NCT05443568	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice	completed	N/A	155	Novo Nordisk A/S
NCT05766709	A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations	completed	PHASE1	53	Novo Nordisk A/S
NCT05669755	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels	active not recruiting	PHASE3	7,101	Novo Nordisk A/S
NCT05502562	A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India	completed	N/A	388	Novo Nordisk A/S
NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	unknown	NA	300	RenJi Hospital
NCT05755360	DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy	completed	N/A	291	Novo Nordisk A/S
NCT06827002	Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults	active not recruiting	PHASE1/PHASE2	248	University of Yaounde 1
NCT07272343	The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes	recruiting	PHASE4	100	Second Affiliated Hospital of Nanchang University
NCT05501483	Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes	recruiting	NA	60	Karolinska Institutet
NCT05394519	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight	completed	PHASE3	1,200	Novo Nordisk A/S
NCT05419726	Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.	recruiting	N/A	20	University of California, Los Angeles
NCT05716724	O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait	completed	N/A	288	Novo Nordisk A/S
NCT05671653	A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range	terminated	PHASE1	32	Pfizer
NCT05579249	A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America	completed	PHASE4	500	Novo Nordisk A/S
NCT05689099	A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose	completed	PHASE1	20	Novo Nordisk A/S
NCT05646706	A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)	completed	PHASE3	1,407	Novo Nordisk A/S
NCT05649137	A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight	completed	PHASE3	512	Novo Nordisk A/S
NCT05597202	Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes	unknown	PHASE4	22	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT05087342	Latino Semaglutide Study	completed	PHASE3	119	Loma Linda University
NCT05616052	Comparison of Body Weight Change Through Different Smeglutide Administration Methods	unknown	PHASE4	80	Huashan Hospital
NCT05768945	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors	completed	N/A	742,670	Brigham and Women's Hospital
NCT05616013	Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese	completed	PHASE2	507	Eli Lilly and Company
NCT05073835	Semaglutide 2.4 mg in Patients With Poor Weight-loss	active not recruiting	PHASE3	70	University College, London
NCT05567796	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	active not recruiting	PHASE3	3,400	Novo Nordisk A/S
NCT04885634	Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients	withdrawn	PHASE3	0	Axel Brandes
NCT05195944	Semaglutide vs Sitagliptin	enrolling by invitation	PHASE4	58	University Health Network, Toronto
NCT05443191	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice	completed	N/A	50	Novo Nordisk A/S
NCT05254314	Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)	recruiting	PHASE2	100	Vanderbilt University Medical Center
NCT05564117	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range	completed	PHASE3	307	Novo Nordisk A/S
NCT05530577	Effects of Semaglutide on Nicotine Intake	completed	PHASE2	24	University of North Carolina, Chapel Hill
NCT05444153	Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity	withdrawn	PHASE3	0	Novo Nordisk A/S
NCT05473286	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice	withdrawn	N/A	0	Novo Nordisk A/S
NCT05371496	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	enrolling by invitation	PHASE2	81	Mayo Clinic
NCT06027567	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	completed	PHASE4	38	Rigmor Højland Jensen
NCT05520775	Semaglutide for Alcohol Use Disorder	completed	PHASE2	48	University of North Carolina, Chapel Hill
NCT05340868	Genetics of the Acute Response to Oral Semaglutide	recruiting	NA	1,000	Medical University of Bialystok
NCT05302596	Semaglutide Use in Elderly Obese Patients	completed	PHASE2	16	State University of New York at Buffalo
NCT05514535	A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)	completed	PHASE3	573	Novo Nordisk A/S
NCT04998136	Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity	completed	PHASE3	150	Novo Nordisk A/S
NCT05498610	A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men	completed	PHASE1	24	Novo Nordisk A/S
NCT05486065	A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight	completed	PHASE2	245	Novo Nordisk A/S
NCT05478252	A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes	completed	PHASE3	388	Novo Nordisk A/S
NCT05443334	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	completed	N/A	465	Novo Nordisk A/S
NCT05548647	Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects	completed	PHASE4	120	University of Pennsylvania
NCT05816057	A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus	completed	PHASE3	476	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
NCT05305794	Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"	recruiting	PHASE3	76	Centre Hospitalier Universitaire Dijon
NCT05442450	Efficacy of Oral Semaglutide in Overweight or Obesity	unknown	PHASE4	116	Asian Institute of Gastroenterology, India
NCT05468632	A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)	completed	N/A	314	Novo Nordisk A/S
NCT05435677	A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together	completed	PHASE1	20	Novo Nordisk A/S
NCT05429593	A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet	completed	PHASE1	152	Novo Nordisk A/S
NCT04174755	Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV	recruiting	NA	80	University College Dublin
NCT05574439	Young Adults With Early-onset Obesity Treated With Semaglutide	completed	PHASE4	246	Signe Torekov
NCT05333003	Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity	active not recruiting	NA	92	Centre for Addiction and Mental Health
NCT05147896	Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients	unknown	NA	100	University Medical Centre Ljubljana
NCT05533632	Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes	completed	PHASE4	104	Novo Nordisk A/S
NCT05230589	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice	completed	N/A	194	Novo Nordisk A/S
NCT05259033	A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)	completed	PHASE3	683	Novo Nordisk A/S
NCT05071898	Pharmacogenetics of Response to GLP1R Agonists	recruiting	PHASE1	600	University of Maryland, Baltimore
NCT05316662	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice	completed	N/A	187	Novo Nordisk A/S
NCT05230615	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	completed	N/A	458	Novo Nordisk A/S
NCT04873245	Lifestyle Counseling and Medication for Adolescent Weight Management	active not recruiting	PHASE2	120	University of Minnesota
NCT04889183	SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes	completed	PHASE3	125	University Medical Center Groningen
NCT05249881	"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."	unknown	EARLY_PHASE1	300	Aga Khan University
NCT05303857	Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes	completed	PHASE4	107	University of Erlangen-Nürnberg Medical School
NCT06301191	The Effect of Semaglutide on Cardiovascular Markers and Liver Function	unknown	N/A	50	Attikon Hospital
NCT04854083	Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes	unknown	PHASE4	50	Kirsi Pietiläinen
NCT07457424	Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)	active not recruiting	N/A	140	University College Dublin
NCT05236517	A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity	completed	PHASE1	60	Novo Nordisk A/S
NCT05227196	A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People	completed	PHASE1	546	Novo Nordisk A/S
NCT04938388	Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care	terminated	PHASE4	12	Sansum Diabetes Research Institute
NCT05078255	The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes	completed	NA	61	Asger Lund, MD
NCT05232708	A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide	completed	PHASE1	18	Novo Nordisk A/S
NCT04873050	Treatment to Regress to Normoglycemia in Women with a Recent History of GDM	recruiting	PHASE4	102	Woman's
NCT06118203	Semaglutide Use in Acute Pulmonary Embolism	completed	N/A	18	Imperial College London
NCT04979130	Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)	completed	PHASE4	69	University of Colorado, Denver
NCT05193578	Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes	completed	PHASE2	154	Jan Frystyk
NCT05857085	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	completed	PHASE4	90	General and Teaching Hospital Celje
NCT05153564	A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause	completed	PHASE1	27	Novo Nordisk A/S
NCT05173714	Sit Less, Interact and Move More (SLIMM) 2 Study	recruiting	PHASE2	156	Srinvasan Beddhu
NCT05071417	Effect Of Semaglutide In Coronary Atheroma Plaque	unknown	PHASE3	120	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
NCT05144984	A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes	completed	PHASE2	500	Novo Nordisk A/S
NCT05119179	Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes	recruiting	PHASE4	300	The University of Texas Health Science Center, Houston
NCT05132088	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity	completed	PHASE3	201	Novo Nordisk A/S
NCT05129891	A Research Study Looking at New Protein-based Tablets in Healthy Male Participants	completed	PHASE1	384	Novo Nordisk A/S
NCT04466345	Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder	completed	PHASE2	72	University Health Network, Toronto
NCT05064735	Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis	completed	PHASE3	407	Novo Nordisk A/S
NCT05606471	Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets	unknown	PHASE4	45	University of Nottingham
NCT05035095	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)	completed	PHASE3	667	Novo Nordisk A/S
NCT04615871	Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	unknown	PHASE2	400	Vladimír Džavík
NCT04817644	A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets	completed	PHASE1	14	Novo Nordisk A/S
NCT05046873	A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People	completed	PHASE1	16	Novo Nordisk A/S
NCT05040971	Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes	completed	PHASE3	207	Novo Nordisk A/S
NCT05035082	A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)	completed	PHASE4	1,020	Novo Nordisk A/S
NCT04892199	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	active not recruiting	PHASE4	104	Anders Fink-Jensen, MD, DMSci
NCT05016882	Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)	completed	PHASE2	698	Novo Nordisk A/S
NCT04624672	Treatment of GLP-1 for Diabetic Bariatric Patients	terminated	PHASE4	3	Geisinger Clinic
NCT04971785	Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	completed	PHASE2	457	Gilead Sciences
NCT04944992	A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)	completed	PHASE2	145	Merck Sharp & Dohme LLC
NCT04982575	Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes	completed	PHASE2	92	Novo Nordisk A/S
NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	terminated	PHASE3	15	Geisinger Clinic
NCT04969939	A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity	completed	PHASE2	120	Novo Nordisk A/S
NCT04940078	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity	completed	PHASE1	40	Novo Nordisk A/S
NCT05577728	Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data	completed	N/A	2,316	Brigham and Women's Hospital
NCT04916470	Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes	completed	PHASE3	617	Novo Nordisk A/S
NCT04865744	The Effect of Semaglutide on Pituitary Function	completed	PHASE4	10	University of Tartu
NCT04878406	A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men	completed	PHASE1	24	Novo Nordisk A/S
NCT04777409	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)	completed	PHASE3	1,840	Novo Nordisk A/S
NCT04777396	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)	completed	PHASE3	1,840	Novo Nordisk A/S
NCT04862923	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice	completed	N/A	336	Novo Nordisk A/S
NCT04878393	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice	completed	N/A	650	Novo Nordisk A/S
NCT04865770	A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)	completed	PHASE3	106	Novo Nordisk A/S
NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	active not recruiting	PHASE3	1,205	Novo Nordisk A/S
NCT04639414	Combined Active Treatment in Type 2 Diabetes with NASH	active not recruiting	PHASE4	192	German Diabetes Center
NCT04788511	Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity	completed	PHASE3	529	Novo Nordisk A/S
NCT04216589	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	completed	PHASE2	51	National Institute of Allergy and Infectious Diseases (NIAID)
NCT04779697	GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight	completed	PHASE1	96	Yale University
NCT04538352	Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D	completed	PHASE4	60	The Cleveland Clinic
NCT04707469	Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes	completed	PHASE3	1,606	Novo Nordisk A/S
NCT04251156	Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.	completed	PHASE3	375	Novo Nordisk A/S
NCT04601740	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice	completed	N/A	145	Novo Nordisk A/S
NCT04601753	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice	completed	N/A	194	Novo Nordisk A/S
NCT04596631	A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	completed	PHASE3	132	Novo Nordisk A/S
NCT04559815	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice	completed	N/A	194	Novo Nordisk A/S
NCT04560998	A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes	completed	PHASE3	792	Novo Nordisk A/S
NCT04524832	Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People	completed	PHASE1	290	Novo Nordisk A/S
NCT06489457	The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity	completed	PHASE3	25	University Medical Centre Ljubljana
NCT04451837	Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology	active not recruiting	PHASE2	200	Region Skane
NCT04515849	A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus	completed	PHASE2	248	AstraZeneca
NCT04513704	A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times	completed	PHASE1	156	Novo Nordisk A/S
NCT04537637	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice	completed	N/A	99	Novo Nordisk A/S
NCT04537624	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice	completed	N/A	194	Novo Nordisk A/S
NCT04469855	Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®	completed	N/A	3,217	Novo Nordisk A/S
NCT04153929	A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.	completed	PHASE2	413	Boehringer Ingelheim
NCT04287179	SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	withdrawn	PHASE3	0	Novo Nordisk A/S
NCT04447859	16-week Flexible vs. 8-week Semaglutide Titration	unknown	PHASE3	100	Tel-Aviv Sourasky Medical Center
NCT04259801	First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes	completed	PHASE1	152	Novo Nordisk A/S
NCT04261933	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)	completed	N/A	789	Novo Nordisk A/S
NCT04238962	A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens	completed	PHASE1	111	Novo Nordisk A/S
NCT04228354	A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide	completed	PHASE1	28	Novo Nordisk A/S
NCT04175665	Real-world Health Outcomes in Canadian Patients Using Semaglutide	completed	N/A	1,133	LMC Diabetes & Endocrinology Ltd.
NCT04187300	A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	completed	PHASE1	68	Novo Nordisk A/S
NCT04383197	Exercise and GLP-1 RA on Insulin Secretion	unknown	NA	30	University of Copenhagen
NCT04189848	Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc	completed	PHASE4	104	Novo Nordisk A/S
NCT04152915	A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens	completed	PHASE1	68	Novo Nordisk A/S
NCT04263415	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	completed	PHASE4	30	University Medical Centre Ljubljana
NCT04061200	Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria	unknown	PHASE4	80	Steno Diabetes Center Copenhagen
NCT04094415	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	completed	N/A	581	Novo Nordisk A/S
NCT04143945	A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	104	Novo Nordisk A/S
NCT04016974	A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese	completed	PHASE1	32	Novo Nordisk A/S
NCT04102189	A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity	completed	PHASE3	201	Novo Nordisk A/S
NCT04109508	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets	completed	PHASE1	278	Novo Nordisk A/S
NCT04109547	A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes	completed	PHASE3	521	Novo Nordisk A/S
NCT04097600	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets	completed	PHASE1	274	Novo Nordisk A/S
NCT04083820	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)	completed	N/A	521	Novo Nordisk A/S
NCT04074161	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity	completed	PHASE3	338	Novo Nordisk A/S
NCT04032197	A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes	completed	PHASE1	101	Novo Nordisk A/S
NCT04067999	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	completed	N/A	230	Novo Nordisk A/S
NCT04126603	Impact of Semaglutide on CD34+ EPC and Fat Derived MSC	completed	PHASE4	10	Sabyasachi Sen
NCT03987919	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	completed	PHASE3	1,879	Eli Lilly and Company
NCT03987074	Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)	completed	PHASE2	109	Gilead Sciences
NCT04017832	A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes	completed	PHASE3	1,441	Novo Nordisk A/S
NCT03884075	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	recruiting	PHASE2	84	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04012255	A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	terminated	PHASE1	29	Novo Nordisk A/S
NCT03951753	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	completed	PHASE1	117	Eli Lilly and Company
NCT04007107	A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	completed	PHASE2	103	Novo Nordisk A/S
NCT03989232	A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	completed	PHASE3	961	Novo Nordisk A/S
NCT03987451	A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage	completed	PHASE2	71	Novo Nordisk A/S
NCT03819153	A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease	completed	PHASE3	3,533	Novo Nordisk A/S
NCT03914326	A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes	completed	PHASE3	9,651	Novo Nordisk A/S
NCT03929679	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)	completed	N/A	218	Novo Nordisk A/S
NCT04019197	Effects of Semaglutide in HIV-Associated Lipohypertrophy	active not recruiting	PHASE2	108	Case Western Reserve University
NCT03811561	A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes	active not recruiting	PHASE3	1,500	Novo Nordisk A/S
NCT03919929	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	completed	PHASE2/PHASE3	60	University of Colorado, Denver
NCT03876015	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)	completed	N/A	215	Novo Nordisk A/S
NCT03899402	Triple Therapy in T1DM	active not recruiting	PHASE2/PHASE3	78	State University of New York at Buffalo
NCT03985384	Semaglutide Treatment On Coronary Progression	completed	PHASE4	140	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NCT03842202	A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity	completed	PHASE1	72	Novo Nordisk A/S
NCT03811574	STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity	completed	PHASE3	401	Novo Nordisk A/S
NCT03789578	A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together	completed	PHASE1	30	Novo Nordisk A/S
NCT03659682	GLP1R in Parkinson's Disease	unknown	PHASE2	120	Oslo University Hospital
NCT03574597	Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity	completed	PHASE3	17,604	Novo Nordisk A/S
NCT03724981	A Study Comparing the Dulaglutide Pen and the Semaglutide Pen	completed	PHASE4	312	Eli Lilly and Company
NCT03292315	Once Weekly GLP-1 in Persons With Spinal Cord Injury	completed	PHASE4	5	James J. Peters Veterans Affairs Medical Center
NCT03707990	A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese	completed	PHASE1	88	Novo Nordisk A/S
NCT03693430	Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	304	Novo Nordisk A/S
NCT03689374	A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes	completed	PHASE3	2,274	Novo Nordisk A/S
NCT03631186	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)	completed	N/A	215	Novo Nordisk A/S
NCT03648281	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)	completed	N/A	333	Novo Nordisk A/S
NCT03638778	Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men	completed	PHASE1	105	Novo Nordisk A/S
NCT03611322	A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)	completed	PHASE1	54	Novo Nordisk A/S
NCT03611582	Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program	completed	PHASE3	611	Novo Nordisk A/S
NCT03600480	A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese	completed	PHASE1	96	Novo Nordisk A/S
NCT03598621	A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools	completed	PHASE1	68	Novo Nordisk A/S
NCT03596450	Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial	completed	PHASE4	1,278	Novo Nordisk A/S
NCT03574584	A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese	completed	PHASE1	37	Novo Nordisk A/S
NCT03548935	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	1,961	Novo Nordisk A/S
NCT03552757	Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity	completed	PHASE3	1,210	Novo Nordisk A/S
NCT03548987	Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	completed	PHASE3	902	Novo Nordisk A/S
NCT03457012	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice	completed	N/A	462	Novo Nordisk A/S
NCT03466567	A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects	completed	PHASE1	21	Novo Nordisk A/S
NCT03357380	A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver	completed	PHASE1	67	Novo Nordisk A/S
NCT03288740	A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects	completed	PHASE1	36	Novo Nordisk A/S
NCT03061214	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)	completed	PHASE3	868	Novo Nordisk A/S
NCT03191396	Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes	completed	PHASE3	577	Novo Nordisk A/S
NCT03136484	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes	completed	PHASE3	788	Novo Nordisk A/S
NCT03086330	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	302	Novo Nordisk A/S
NCT03021187	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin	completed	PHASE3	731	Novo Nordisk A/S
NCT02692716	A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE3	3,183	Novo Nordisk A/S
NCT03018028	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	243	Novo Nordisk A/S
NCT03015220	Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	458	Novo Nordisk A/S
NCT03010475	A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects	completed	PHASE1	41	Novo Nordisk A/S
NCT02970942	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	completed	PHASE2	320	Novo Nordisk A/S
NCT02920385	A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.	completed	PHASE1	45	Novo Nordisk A/S
NCT02849080	Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.	completed	PHASE3	504	Novo Nordisk A/S
NCT02906930	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only	completed	PHASE3	703	Novo Nordisk A/S
NCT02827708	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment	completed	PHASE3	324	Novo Nordisk A/S
NCT02877355	Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.	completed	PHASE1	55	Novo Nordisk A/S
NCT02863328	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	822	Novo Nordisk A/S
NCT02863419	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus	completed	PHASE3	711	Novo Nordisk A/S
NCT02845219	A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females	completed	PHASE1	25	Novo Nordisk A/S
NCT02773381	A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes	completed	PHASE1	15	Novo Nordisk A/S
NCT02607865	Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	completed	PHASE3	1,864	Novo Nordisk A/S
NCT02648204	Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.	completed	PHASE3	1,201	Novo Nordisk A/S
NCT02453711	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus	completed	PHASE2	957	Novo Nordisk A/S
NCT02557620	Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly	completed	PHASE1	113	Novo Nordisk A/S
NCT02461589	Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes	completed	PHASE2	706	Novo Nordisk A/S
NCT02305381	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes	completed	PHASE3	397	Novo Nordisk A/S
NCT02254291	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	308	Novo Nordisk A/S
NCT02231684	Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide	completed	PHASE1	42	Novo Nordisk A/S
NCT02249871	Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	completed	PHASE1	54	Novo Nordisk A/S
NCT02249910	Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects	completed	PHASE1	32	Novo Nordisk A/S
NCT02243098	Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects	completed	PHASE1	31	Novo Nordisk A/S
NCT02212067	A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes	completed	PHASE1	87	Novo Nordisk A/S
NCT02210871	Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function	completed	PHASE1	44	Novo Nordisk A/S
NCT02128932	Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes	completed	PHASE3	1,089	Novo Nordisk A/S
NCT02207374	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes	completed	PHASE3	601	Novo Nordisk A/S
NCT02172313	Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	completed	PHASE1	78	Novo Nordisk A/S
NCT02161588	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	48	Novo Nordisk A/S
NCT02147431	A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	completed	PHASE1	38	Novo Nordisk A/S
NCT02146079	A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	44	Novo Nordisk A/S
NCT02079870	Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo	completed	PHASE1	30	Novo Nordisk A/S
NCT02070510	A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects	completed	PHASE1	52	Novo Nordisk A/S
NCT02064348	A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects	completed	PHASE1	168	Novo Nordisk A/S
NCT02060266	Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects	completed	PHASE1	7	Novo Nordisk A/S
NCT02054897	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes	completed	PHASE3	388	Novo Nordisk A/S
NCT02022254	Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects	completed	PHASE1	24	Novo Nordisk A/S
NCT02016911	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment	completed	PHASE1	56	Novo Nordisk A/S
NCT02014259	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function	completed	PHASE1	71	Novo Nordisk A/S
NCT01885208	Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes	completed	PHASE3	813	Novo Nordisk A/S
NCT01930188	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes	completed	PHASE3	1,231	Novo Nordisk A/S
NCT01923181	Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE2	632	Novo Nordisk A/S
NCT01866748	Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects	completed	PHASE1	170	Novo Nordisk A/S
NCT01720446	Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE3	3,297	Novo Nordisk A/S
NCT01766245	A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes	completed	PHASE1	28	Novo Nordisk A/S
NCT01686945	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes	completed	PHASE1	107	Novo Nordisk A/S
NCT01619345	Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects	completed	PHASE1	27	Novo Nordisk A/S
NCT01572753	Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects	completed	PHASE1	161	Novo Nordisk A/S
NCT01324505	Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes	completed	PHASE1	43	Novo Nordisk A/S
NCT01272973	Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects	completed	PHASE1	96	Novo Nordisk A/S
NCT00851773	Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects	completed	PHASE1	84	Novo Nordisk A/S
NCT00833716	Effect of Renal Impairment on the Pharmacokinetics of NN9535	completed	PHASE1	62	Novo Nordisk A/S
NCT00813020	A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects	completed	PHASE1	44	Novo Nordisk A/S
NCT00696657	A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	completed	PHASE2	415	Novo Nordisk A/S
NCT03144271	Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects	completed	PHASE1	58	Novo Nordisk A/S
NCT06863363	PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults	not yet recruiting	PHASE4	212	Shanghai Zhongshan Hospital

Where to Participate: All Semaglutide Trial Sites in the U.S. (195 sites across 37 states)

Every actively recruiting Semaglutidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Cahaba Research	Pelham35124	NCT07564414	Map
AZ	Kailera Clinical Site	Glendale85308	NCT07284979	Map
AZ	DM Clinical Research - Phoenix	Phoenix85012	NCT07446998	Map
AZ	Kailera Clinical Site	Phoenix85012	NCT07284979	Map
AZ	Velocity Clinical Research-Phoenix	Phoenix85006	NCT07564414	Map
AR	Arkansas Clinical Research	Little Rock72205	NCT07564414	Map
AR	Kailera Clinical Site	Little Rock72205	NCT07284979	Map
CA	Altasciences Clinical LA, Inc.	Cypress90630	NCT07225816	Map
CA	City of Hope Medical Center	Duarte91010	NCT07202247	Map
CA	Headlands Research California, LLC	Escondido92025	NCT07564414	Map
CA	Neighborhood Healthcare	Escondido92025	NCT07564414	Map
CA	Diabetes & Endocrine Specialists - La Mesa	La Mesa91942	NCT07564414	Map
CA	First Valley Medical Group	Lancaster93534	NCT07415954	Map
CA	Clinical Trials Research_Sacramento	Lincoln95648	NCT07564414	Map
CA	Torrance Clinical Research Institute, Inc.	Lomita90717	NCT07415954	Map
CA	Ark Clinical Research	Long Beach90815	NCT07415954	Map
CA	Pacific Clinical Studies	Los Alamitos90720	NCT07415954	Map
CA	Pacific Clinical Studies	Los Alamitos90720	NCT07564414	Map
CA	UCLA Health	Los Angeles90095	NCT05419726	Map
CA	Kailera Clinical Site	Northridge91325	NCT07284979	Map
CA	Valley Clinical Trials	Northridge91325	NCT07564414	Map
CA	Kailera Clinical Site	Oceanside92058	NCT07284979	Map
CA	Desert Oasis Healthcare	Palm Springs92262	NCT07564414	Map
CA	Greenstone Biosciences	Palo Alto94304	NCT06541509	Map
CA	Linda Vista Health Care Ctr	San Diego92111	NCT07564414	Map
CA	Wetlin Research Associates, Inc.	San Diego92120	NCT07415954	Map
CA	Center on Substance Use and Health	San Francisco94102	NCT07204249	Map
CA	Stanford Cardiovascular Institute	Stanford94305	NCT06541509	Map
CA	Stanford University	Stanford94305	NCT05173714	Map
CA	Velocity Clin Res - Van Nuys	Van Nuys91405	NCT07564414	Map
CA	Diablo Clinical Research, Inc.	Walnut Creek94598	NCT07415954	Map
CA	Flourish Research - CA	Walnut Creek94598	NCT07564414	Map
CO	Childrens Hospital Colorado	Aurora80045	NCT06575738	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT05819138	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT05822609	Map
CO	University of Colorado Anschutz/Children's Hospital Colorado Aurora	Aurora80045	NCT05819853	Map
CO	University of Colorado-School of Medicine	Aurora80045	NCT06975111	Map
CT	Kailera Clinical Site	Hamden06517	NCT07284979	Map
CT	Yale Pediatric Diabetes Center, Adult and Children's Progam	New Haven06520	NCT06411210	Map
CT	Yale School of Medicine	New Haven06520	NCT07223983	Map
CT	Kailera Clinical Site	Stamford06905	NCT07284979	Map
DC	Institute of Human Virology at the University of Maryland School of Medicine	Washington D.C.20002	NCT06691243	Map
FL	TBMR & Alcanza	Clearwater33761	NCT07564414	Map
FL	DM Clinical Research - MIA	Doral33166	NCT07446998	Map
FL	Universal Axon Clinical Research (Rovia - UACR)	Doral33166	NCT07446998	Map
FL	Northeast Research Institute	Fleming Island32003	NCT07564414	Map
FL	Encore Medical Research LLC	Hollywood33024	NCT07253285	Map
FL	Encore Medical Research LLC	Hollywood33024	NCT07415954	Map
FL	Northeast Research Institute	Jacksonville32204	NCT07564414	Map
FL	Bioclinical Research Alliance	Miami33155	NCT07415954	Map
FL	Bioclinical Research Alliance	Miami33155	NCT07564414	Map
FL	IMIC Research a Rovia Clinical Research Company	Miami33176	NCT07446998	Map
FL	New Horizon Research Center	Miami33165	NCT07564414	Map
FL	Paramo Health	Miami33175	NCT07446998	Map
FL	Paramo Health	Miami33176	NCT07446998	Map
FL	South Broward Research LLC	Miramar33027	NCT07415954	Map
FL	South Broward Research LLC	Miramar33027	NCT07564414	Map
FL	West Orange Endocrinology	Ocoee34761	NCT07564414	Map
FL	Kailera Clinical Site	Orange City32763	NCT07284979	Map
FL	Advent Health-Res Inst	Orlando32804	NCT07184086	Map
FL	Oviedo Medical Research, LLC	Oviedo32765	NCT07564414	Map
FL	Encore Medical Research of Weston	Weston33331	NCT07253285	Map
FL	Encore Medical Research of Weston	Weston33331	NCT07415954	Map
GA	Kailera Clinical Site	Albany31707	NCT07284979	Map
GA	Children's Healthcare Atlanta	Atlanta30329	NCT07253285	Map
GA	UD Research	Atlanta30342	NCT07446998	Map
GA	Columbus Research Foundation	Columbus31904	NCT07253285	Map
GA	Hope Clin Res & Wellness	Conyers30094	NCT07564414	Map
GA	Accel Research Sites-NeuroStudies	Decatur30030	NCT07253285	Map
GA	Atlanta VA Medical Center	Decatur30033	NCT07040592	Map
GA	Center for Adv Res & Education	Gainesville30501	NCT07564414	Map
GA	Endocrine Research Solutions, Inc	Roswell30076	NCT07564414	Map
GA	Eastside Bariatric and Gen Surg	Snellville30078	NCT07253285	Map
GA	North Georgia Clinical Research	Woodstock30189-4255	NCT07564414	Map
ID	Elite Clinical Trials	Blackfoot83221	NCT07415954	Map
ID	Solaris Clinical Research	Meridian83646	NCT07564414	Map
IL	Cedar-Crosse Research Center	Chicago60607	NCT07415954	Map
IL	Kailera Clinical Site	Chicago60640	NCT07284979	Map
IL	University of Chicago	Chicago60637	NCT06499857	Map
IL	Macoupin Fam Practice Ctr, LLP	Gillespie62033	NCT07564414	Map
IL	Clinical Investigation Spec Gurnee	Gurnee60031	NCT07564414	Map
IL	Evanston Premier Hlthcr Res	Skokie60077	NCT07564414	Map
IL	Kailera Clinical Site	Skokie60077	NCT07284979	Map
IN	IU Health - Riley Physicians Endo-Diab	Indianapolis46202	NCT07253285	Map
KS	Alliance for Multispecialty Research	Newton67114	NCT07564414	Map
KS	Kailera Clinical Site	Newton67114	NCT07284979	Map
KS	Cotton O'Neil Diab & Endo Ctr	Topeka66606	NCT07564414	Map
KY	The Research Group of Lexington LLC	Lexington40503	NCT07564414	Map
LA	Pennington Biomed Res Ctr	Baton Rouge70808-4124	NCT07184086	Map
LA	Pennington Biomed Res Ctr	Baton Rouge70808-4124	NCT07253285	Map
LA	Pennington Biomedical Research Center	Baton Rouge70808	NCT07446998	Map
LA	Woman's Hospital	Baton Rouge70817	NCT04873050	Map
LA	Kailera Clinical Site	Shreveport71105	NCT07284979	Map
MD	Institute of Human Virology at the University of Maryland School of Medicine	Baltimore21201	NCT06691243	Map
MD	National Institute on Drug Abuse	Baltimore21224	NCT06015893	Map
MD	University of Maryland Baltimore	Baltimore21223	NCT06548490	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT03884075	Map
MD	Centennial Medical Group (CMG)	Columbia21045	NCT07446998	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06639464	Map
MA	Massachusetts General Hospital	Boston02114	NCT06003153	Map
MI	Northern Pines Hlth Ctr, PC	Buckley49620	NCT07564414	Map
MI	Kailera Clinical Site	Farmington Hills48334	NCT07284979	Map
MN	University of Minnesota	Minneapolis55455	NCT07253285	Map
MN	AES Minneapolis DRS	Richfield55423	NCT07564414	Map
MN	Mayo Clinic	Rochester55905	NCT07213466	Map
MS	SKY Integrative Medical Center	Ridgeland39157	NCT07446998	Map
MO	Clinical Research Professionals	Chesterfield63005	NCT07564414	Map
MO	Headlands Research	Springfield65807	NCT07415954	Map
MO	Amicis Centers of Clinical Research	St Louis63128	NCT07564414	Map
MO	Washington University School of Medicine	St Louis63110	NCT07091500	Map
MT	Kailera Clinical Site	Missoula59804	NCT07284979	Map
NV	Kailera Clinical Site	Las Vegas89148	NCT07284979	Map
NJ	Frontage Clinical Services, Inc.	Secaucus07094	NCT07465965	Map
NY	Kailera Clinical Site	Albany12203	NCT07284979	Map
NY	NYU Langone Health	New York10016	NCT06548490	Map
NY	Southgate Medical Group, LLP	West Seneca14224	NCT07564414	Map
NC	PharmQuest	Greensboro27408	NCT07415954	Map
NC	PharmQuest Life Sciences LLC	Greensboro27408	NCT07564414	Map
NC	Physician's East Endocrinology	Greenville27834	NCT07564414	Map
NC	Carteret Medical Group	Morehead City28557	NCT07564414	Map
NC	Centricity Rsrch MHCity Multi	Morehead City28557	NCT07564414	Map
NC	Kailera Clinical Site	Morehead City28557	NCT07284979	Map
NC	Piedmont Healthcare Statesville	Statesville28625	NCT07415954	Map
NC	Piedmont Healthcare/Research	Statesville28625	NCT07564414	Map
NC	Accellacare Wilmington	Wilmington28401	NCT07564414	Map
ND	Lillestol Research LLC	Fargo58104	NCT07564414	Map
OH	Providence Center for Clinical Research	Dayton45439	NCT07415954	Map
OH	Advanced Medical Research	Maumee43537	NCT07564414	Map
OK	Alliance for Multispecialty Research	Norman73069	NCT07564414	Map
OK	Kailera Clinical Site	Norman73069	NCT07284979	Map
OK	Lynn Institute of Norman	Norman73072	NCT07564414	Map
OK	Health Promotion Research Center	Oklahoma City73104	NCT06986993	Map
PA	Pennsylvania Psychiatric Institute	Harrisburg17110	NCT06548490	Map
PA	Hatboro Med Associates	Hatboro19040	NCT07564414	Map
PA	Amish Research Clinic	Lancaster17602	NCT05071898	Map
PA	University of Pennsylvania Perelman School of Medicine	Philadelphia19104	NCT05746039	Map
RI	Clinical Res Collaborative	Cumberland02864	NCT07564414	Map
RI	Kailera Clinical Site	East Greenwich02818	NCT07284979	Map
SC	Kailera Clinical Site	North Charleston29405	NCT07284979	Map
SC	Kailera Clinical Site	Spartanburg29303	NCT07284979	Map
SC	Spartanburg Medical Research	Spartanburg29303	NCT07564414	Map
TN	Jackson Clinic	Jackson38305	NCT07564414	Map
TN	Holston Medical Group	Kingsport37660	NCT07564414	Map
TN	CNS Healthcare	Memphis38119	NCT07415954	Map
TN	CNS Healthcare	Memphis38119	NCT07564414	Map
TN	HealthStar Physicians, PC	Morristown37813	NCT07564414	Map
TN	Clinical Research Associates	Nashville37203	NCT07564414	Map
TN	Vanderbilt University Medical Center	Nashville37203	NCT05254314	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06338553	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT07221214	Map
TX	Amarillo Med Spec LLP	Amarillo79124	NCT07564414	Map
TX	Texas Diab & Endo, P.A.	Austin78731	NCT07564414	Map
TX	The University of Texas at Austin	Austin78723	NCT06173778	Map
TX	Velocity Clinical Research Austin	Austin78759	NCT07564414	Map
TX	Kailera Clinical Site	Brownsville78526	NCT07284979	Map
TX	UTHealth Clinical Research Unit (CRU) at UT Brownsville	Brownsville78520	NCT05119179	Map
TX	North Texas Endocrine Center	Dallas75231	NCT07564414	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT07361874	Map
TX	University of Texas Southwestern Medical Center	Dallas75390-9302	NCT07415954	Map
TX	Velocity Clin Res, Dallas	Dallas75230	NCT07564414	Map
TX	DM Clinical	Houston77065	NCT07253285	Map
TX	JCCT- Juno NW Houston	Houston77040	NCT07415954	Map
TX	JCCT- Juno NW Houston	Houston77040	NCT07564414	Map
TX	The Endocrine Center	Houston77079	NCT07564414	Map
TX	The University of Texas Health Science Center at Houston	Houston77054	NCT06173778	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT07227948	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT07325500	Map
TX	Sante Clinical Research	Kerrville78028	NCT07564414	Map
TX	Radiance Clinical Research	Lampasas76550	NCT07564414	Map
TX	Aeres Clinical Research	Laredo78041	NCT07564414	Map
TX	DCOL Ctr for Clin Res	Longview75605	NCT07564414	Map
TX	RGV Endocrine Center	McAllen78503	NCT07564414	Map
TX	AES San Antonio	San Antonio78229	NCT07564414	Map
TX	Kailera Clinical Site	San Antonio78229	NCT07284979	Map
TX	Northeast Clinical Research of San Antonio	San Antonio78233	NCT07564414	Map
TX	Quality Research Inc	San Antonio78209	NCT07564414	Map
TX	University Health - Texas Diabetic Institute	San Antonio78207	NCT06706284	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06706284	Map
TX	Consano Clinical Research, LLC	Shavano Park78231	NCT07415954	Map
TX	Consano Clinical Research, LLC	Shavano Park78231	NCT07564414	Map
TX	Mt Olympus Medical Research, LLC	Sugar Land77478	NCT07564414	Map
UT	J.Lewis Research Inc	Salt Lake City84109	NCT07564414	Map
UT	J.Lewis Research Inc	Salt Lake City84121	NCT07564414	Map
UT	University of Utah	Salt Lake City84108	NCT05173714	Map
UT	J.Lewis Research Inc	South Jordan84095	NCT07564414	Map
VA	Kailera Clinical Site	Manassas20110	NCT07284979	Map
VA	Health Res of Hampton Roads	Newport News23606	NCT07564414	Map
VA	Tidewater Physicians Multispecialty Group	Newport News23606	NCT07564414	Map
VA	Kailera Clinical Site	Richmond23236	NCT07284979	Map
VA	National Clin Res Inc.	Richmond23294	NCT07564414	Map
VA	Virginia Commonwealth University	Richmond23298	NCT05424003	Map
WA	University of Washington	Seattle98104	NCT05822609	Map
WA	University of Washington - Harborview Medical Center	Seattle98104	NCT05780905	Map
WA	University of Washington Medicine Diabetes Institute (UWMDI)	Seattle98109	NCT05819138	Map
WA	Providence Sacred Heart Medical Center	Spokane99204	NCT05822609	Map

Browse Semaglutide Trials by State

Texas clinical trials Colorado clinical trials Florida clinical trials Maryland clinical trials Louisiana clinical trials Massachusetts clinical trials Tennessee clinical trials Washington clinical trials Illinois clinical trials Arizona clinical trials

semaglutidediabetes mellitus, type 2obesitydiabetestype 2 diabetesoverweightclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated May 12, 2026.

Recent Semaglutide updates

What Is Semaglutide?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Semaglutide Development Timeline

Conditions Under Study

All Semaglutide Clinical Trials (537)

Sponsors

Where to Participate: All Semaglutide Trial Sites in the U.S. (195 sites across 37 states)

Browse Semaglutide Trials by State